

Richard F Greil

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4531965/publications.pdf>

Version: 2024-02-01

624
papers

32,792
citations

5248

83
h-index

6113

159
g-index

638
all docs

638
docs citations

638
times ranked

31522
citing authors

#	ARTICLE	IF	CITATIONS
1	Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study. <i>Lancet, The</i> , 2019, 394, 1915-1928.	6.3	1,804
2	Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial. <i>Lancet Oncology, The</i> , 2013, 14, 29-37.	5.1	997
3	Endocrine Therapy plus Zoledronic Acid in Premenopausal Breast Cancer. <i>New England Journal of Medicine</i> , 2009, 360, 679-691.	13.9	976
4	Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial. <i>Lancet, The</i> , 2005, 366, 455-462.	6.3	828
5	Reduced Treatment Intensity in Patients with Early-Stage Hodgkin's Lymphoma. <i>New England Journal of Medicine</i> , 2010, 363, 640-652.	13.9	824
6	Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer. <i>New England Journal of Medicine</i> , 2020, 382, 597-609.	13.9	789
7	A New Molecular Predictor of Distant Recurrence in ER-Positive, HER2-Negative Breast Cancer Adds Independent Information to Conventional Clinical Risk Factors. <i>Clinical Cancer Research</i> , 2011, 17, 6012-6020.	3.2	597
8	Multicenter Phase II Study of Lapatinib in Patients with Brain Metastases from HER2-Positive Breast Cancer. <i>Clinical Cancer Research</i> , 2009, 15, 1452-1459.	3.2	592
9	Phase II Randomized Study of Neoadjuvant Everolimus Plus Letrozole Compared With Placebo Plus Letrozole in Patients With Estrogen Receptor-Positive Breast Cancer. <i>Journal of Clinical Oncology</i> , 2009, 27, 2630-2637.	0.8	582
10	Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin's lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trial. <i>Lancet, The</i> , 2012, 379, 1791-1799.	6.3	564
11	Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial. <i>Lancet Oncology, The</i> , 2019, 20, 43-56.	5.1	448
12	Adjuvant denosumab in breast cancer (ABCSG-18): a multicentre, randomised, double-blind, placebo-controlled trial. <i>Lancet, The</i> , 2015, 386, 433-443.	6.3	444
13	Randomized Phase III Trial Comparing Biweekly Infusional Fluorouracil/Leucovorin Alone or With Irinotecan in the Adjuvant Treatment of Stage III Colon Cancer: PETACC-3. <i>Journal of Clinical Oncology</i> , 2009, 27, 3117-3125.	0.8	437
14	Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial. <i>Lancet Oncology, The</i> , 2011, 12, 631-641.	5.1	427
15	Intensified Chemotherapy and Dose-Reduced Involved-Field Radiotherapy in Patients With Early Unfavorable Hodgkin's Lymphoma: Final Analysis of the German Hodgkin Study Group HD11 Trial. <i>Journal of Clinical Oncology</i> , 2010, 28, 4199-4206.	0.8	397
16	Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy. <i>Lancet Oncology, The</i> , 2008, 9, 840-849.	5.1	345
17	Predicting distant recurrence in receptor-positive breast cancer patients with limited clinicopathological risk: using the PAM50 Risk of Recurrence score in 1478 postmenopausal patients of the ABCSG-8 trial treated with adjuvant endocrine therapy alone. <i>Annals of Oncology</i> , 2014, 25, 339-345.	0.6	326
18	Dabrafenib plus trametinib in patients with BRAFV600E-mutated biliary tract cancer (ROAR): a phase 2, open-label, single-arm, multicentre basket trial. <i>Lancet Oncology, The</i> , 2020, 21, 1234-1243.	5.1	297

#	ARTICLE	IF	CITATIONS
19	Randomized Phase II Study of the Anti-epidermal Growth Factor Receptor Monoclonal Antibody Cetuximab With Cisplatin Versus Cisplatin Alone in Patients With Metastatic Triple-Negative Breast Cancer. <i>Journal of Clinical Oncology</i> , 2013, 31, 2586-2592.	0.8	296
20	Extended Adjuvant Therapy With Anastrozole Among Postmenopausal Breast Cancer Patients: Results From the Randomized Austrian Breast and Colorectal Cancer Study Group Trial 6a. <i>Journal of the National Cancer Institute</i> , 2007, 99, 1845-1853.	3.0	288
21	The EndoPredict score provides prognostic information on late distant metastases in ER+/HER2- breast cancer patients. <i>British Journal of Cancer</i> , 2013, 109, 2959-2964.	2.9	288
22	Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma. <i>New England Journal of Medicine</i> , 2022, 386, 351-363.	13.9	278
23	PET-guided treatment in patients with advanced-stage Hodgkin's lymphoma (HD18): final results of an open-label, international, randomised phase 3 trial by the German Hodgkin Study Group. <i>Lancet</i> , The, 2017, 390, 2790-2802.	6.3	274
24	Dose-Intensification in Early Unfavorable Hodgkin's Lymphoma: Final Analysis of the German Hodgkin Study Group HD14 Trial. <i>Journal of Clinical Oncology</i> , 2012, 30, 907-913.	0.8	273
25	Phase III Study of Capecitabine Plus Oxaliplatin Compared With Fluorouracil and Leucovorin Plus Oxaliplatin in Metastatic Colorectal Cancer: A Final Report of the AIO Colorectal Study Group. <i>Journal of Clinical Oncology</i> , 2007, 25, 4217-4223.	0.8	258
26	Zoledronic acid combined with adjuvant endocrine therapy of tamoxifen versus anastrozol plus ovarian function suppression in premenopausal early breast cancer: final analysis of the Austrian Breast and Colorectal Cancer Study Group Trial 12. <i>Annals of Oncology</i> , 2015, 26, 313-320.	0.6	251
27	AVEREL: A Randomized Phase III Trial Evaluating Bevacizumab in Combination With Docetaxel and Trastuzumab As First-Line Therapy for HER2-Positive Locally Recurrent/Metastatic Breast Cancer. <i>Journal of Clinical Oncology</i> , 2013, 31, 1719-1725.	0.8	247
28	First-Line Treatment of Advanced Breast Cancer With Sunitinib in Combination With Docetaxel Versus Docetaxel Alone: Results of a Prospective, Randomized Phase III Study. <i>Journal of Clinical Oncology</i> , 2012, 30, 921-929.	0.8	244
29	Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma. <i>New England Journal of Medicine</i> , 2022, 386, 629-639.	13.9	243
30	Remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 (DisCoVeRy): a phase 3, randomised, controlled, open-label trial. <i>Lancet Infectious Diseases</i> , The, 2022, 22, 209-221.	4.6	233
31	Midostaurin added to chemotherapy and continued single-agent maintenance therapy in acute myeloid leukemia with FLT3-ITD. <i>Blood</i> , 2019, 133, 840-851.	0.6	228
32	Polyacetylenes from the Apiaceae Vegetables Carrot, Celery, Fennel, Parsley, and Parsnip and Their Cytotoxic Activities. <i>Journal of Agricultural and Food Chemistry</i> , 2005, 53, 2518-2523.	2.4	223
33	Thalidomide-dexamethasone compared with melphalan-prednisolone in elderly patients with multiple myeloma. <i>Blood</i> , 2009, 113, 3435-3442.	0.6	213
34	T cells in multiple myeloma display features of exhaustion and senescence at the tumor site. <i>Journal of Hematology and Oncology</i> , 2016, 9, 116.	6.9	201
35	Rpeginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and Tj ETQq1 1 0.784314 rgBT /Overlock 10 Tf 50 Haematology,the, 2020, 7, e196-e208.	2.2	199
36	Prognostic factors for remission of and survival in acquired hemophilia A (AHA): results from the GTH-AH 01/2010 study. <i>Blood</i> , 2015, 125, 1091-1097.	0.6	197

#	ARTICLE	IF	CITATIONS
37	Impact of Body Mass Index on the Efficacy of Endocrine Therapy in Premenopausal Patients With Breast Cancer: An Analysis of the Prospective ABCSG-12 Trial. <i>Journal of Clinical Oncology</i> , 2011, 29, 2653-2659.	0.8	196
38	Eight Cycles of Escalated-Dose BEACOPP Compared With Four Cycles of Escalated-Dose BEACOPP Followed by Four Cycles of Baseline-Dose BEACOPP With or Without Radiotherapy in Patients With Advanced-Stage Hodgkin's Lymphoma: Final Analysis of the HD12 Trial of the German Hodgkin Study Group. <i>Journal of Clinical Oncology</i> , 2011, 29, 4234-4242.	0.8	183
39	The PAM50 Risk-of-Recurrence Score Predicts Risk for Late Distant Recurrence after Endocrine Therapy in Postmenopausal Women with Endocrine-Responsive Early Breast Cancer. <i>Clinical Cancer Research</i> , 2014, 20, 1298-1305.	3.2	182
40	Resveratrol, a tumor-suppressive compound from grapes, induces apoptosis via a novel mitochondrial pathway controlled by Bcl-2. <i>FASEB Journal</i> , 2001, 15, 1613-1615.	0.2	175
41	Comparison of Two Quality-of-Life Instruments for Cancer Patients: The Functional Assessment of Cancer Therapy-General and the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30. <i>Journal of Clinical Oncology</i> , 1999, 17, 2932-2932.	0.8	173
42	EndoPredict improves the prognostic classification derived from common clinical guidelines in ER-positive, HER2-negative early breast cancer. <i>Annals of Oncology</i> , 2013, 24, 640-647.	0.6	170
43	Adjuvant denosumab in postmenopausal patients with hormone receptor-positive breast cancer (ABCSG-18): disease-free survival results from a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet Oncology</i> , The, 2019, 20, 339-351.	5.1	167
44	Clinical impact of DNMT3A mutations in younger adult patients with acute myeloid leukemia: results of the AML Study Group (AMLSG). <i>Blood</i> , 2013, 121, 4769-4777.	0.6	162
45	Omission of dacarbazine or bleomycin, or both, from the ABVD regimen in treatment of early-stage favourable Hodgkin's lymphoma (GHSG HD13): an open-label, randomised, non-inferiority trial. <i>Lancet</i> , The, 2015, 385, 1418-1427.	6.3	154
46	Phase III Trial of Sunitinib in Combination With Capecitabine Versus Capecitabine Monotherapy for the Treatment of Patients With Pretreated Metastatic Breast Cancer. <i>Journal of Clinical Oncology</i> , 2013, 31, 2870-2878.	0.8	151
47	Positron Emission Tomography-Guided Treatment in Early-Stage Favorable Hodgkin Lymphoma: Final Results of the International, Randomized Phase III HD16 Trial by the German Hodgkin Study Group. <i>Journal of Clinical Oncology</i> , 2019, 37, 2835-2845.	0.8	151
48	Randomized phase II study of lapatinib plus capecitabine or lapatinib plus topotecan for patients with HER2-positive breast cancer brain metastases. <i>Journal of Neuro-Oncology</i> , 2011, 105, 613-620.	1.4	149
49	Resveratrol causes arrest in the S-phase prior to Fas-independent apoptosis in CEM-C7H2 acute leukemia cells. <i>Cell Death and Differentiation</i> , 2000, 7, 834-842.	5.0	148
50	Lenalidomide Maintenance Compared With Placebo in Responding Elderly Patients With Diffuse Large B-Cell Lymphoma Treated With First-Line Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone. <i>Journal of Clinical Oncology</i> , 2017, 35, 2473-2481.	0.8	148
51	HER2 Directed Antibody-Drug-Conjugates beyond T-DM1 in Breast Cancer. <i>International Journal of Molecular Sciences</i> , 2019, 20, 1115.	1.8	144
52	Ropeginterferon alfa-2b, a novel IFN-2b, induces high response rates with low toxicity in patients with polycythemia vera. <i>Blood</i> , 2015, 126, 1762-1769.	0.6	142
53	Light Chain-Induced Acute Renal Failure Can Be Reversed by Bortezomib-Doxorubicin-Dexamethasone in Multiple Myeloma: Results of a Phase II Study. <i>Journal of Clinical Oncology</i> , 2010, 28, 4635-4641.	0.8	133
54	Impact of Breast Surgery in Primary Metastasized Breast Cancer. <i>Annals of Surgery</i> , 2019, 269, 1163-1169.	2.1	130

#	ARTICLE	IF	CITATIONS
55	Constitutive Expression of Fas (Apo-1/CD95) Ligand on Multiple Myeloma Cells: A Potential Mechanism of Tumor-Induced Suppression of Immune Surveillance. <i>Blood</i> , 1997, 90, 12-20.	0.6	129
56	Molecular and cellular mechanisms of CLL: novel therapeutic approaches. <i>Nature Reviews Clinical Oncology</i> , 2009, 6, 405-418.	12.5	129
57	The impact of hemoglobin levels on fatigue and quality of life in cancer patients. <i>Annals of Oncology</i> , 2002, 13, 965-973.	0.6	128
58	Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: phase III randomized LUX-Lung 5 trial. <i>Annals of Oncology</i> , 2016, 27, 417-423.	0.6	122
59	Protocol-specified final analysis of the phase 3 KEYNOTE-048 trial of pembrolizumab (pembro) as first-line therapy for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC).. <i>Journal of Clinical Oncology</i> , 2019, 37, 6000-6000.	0.8	118
60	Interdependent regulation of p53 and miR-34a in chronic lymphocytic leukemia. <i>Cell Cycle</i> , 2010, 9, 2836-2840.	1.3	116
61	Longitudinal analysis of 2293 NSCLC patients: A comprehensive study from the TYROL registry. <i>Lung Cancer</i> , 2015, 87, 193-200.	0.9	115
62	Low-Dose Radiation Is Sufficient for the Noninvolved Extended-Field Treatment in Favorable Early-Stage Hodgkin's Disease: Long-Term Results of a Randomized Trial of Radiotherapy Alone. <i>Journal of Clinical Oncology</i> , 2001, 19, 2905-2914.	0.8	114
63	Expression of functional interleukin-15 receptor and autocrine production of interleukin-15 as mechanisms of tumor propagation in multiple myeloma. <i>Blood</i> , 2000, 95, 610-618.	0.6	111
64	Normative data for functional assessment of cancer therapy General scale and its use for the interpretation of quality of life scores in cancer survivors. <i>Acta Oncologica</i> , 2004, 43, 153-160.	0.8	109
65	Identification of differential and functionally active miRNAs in both anaplastic lymphoma kinase (ALK) and ALK ⁺ anaplastic large-cell lymphoma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2010, 107, 16228-16233.	3.3	108
66	Identifying clinically relevant prognostic subgroups of postmenopausal women with node-positive hormone receptor-positive early-stage breast cancer treated with endocrine therapy: a combined analysis of ABCSG-8 and ATAC using the PAM50 risk of recurrence score and intrinsic subtype. <i>Annals of Oncology</i> , 2015, 26, 1685-1691.	0.6	108
67	Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer: interim efficacy results of the randomised, open-label, non-inferiority, phase 3 TURANDOT trial. <i>Lancet Oncology</i> , The, 2013, 14, 125-133.	5.1	107
68	CYP2D6 Metabolism and Patient Outcome in the Austrian Breast and Colorectal Cancer Study Group Trial (ABCSG) 8. <i>Clinical Cancer Research</i> , 2013, 19, 500-507.	3.2	107
69	AID/APOBEC deaminases and cancer. <i>Oncoscience</i> , 2015, 2, 320-333.	0.9	105
70	Differential Sensitivity of CD4+ and CD8+ T Lymphocytes to the Killing Efficacy of Fas (Apo-1/CD95) Ligand+ Tumor Cells in B Chronic Lymphocytic Leukemia. <i>Blood</i> , 1998, 91, 4273-4281.	0.6	100
71	microRNA-34a expression correlates with MDM2 SNP309 polymorphism and treatment-free survival in chronic lymphocytic leukemia. <i>Blood</i> , 2010, 115, 4191-4197.	0.6	99
72	Rituximab serum concentrations during immuno-chemotherapy of follicular lymphoma correlate with patient gender, bone marrow infiltration and clinical response. <i>Haematologica</i> , 2012, 97, 1431-1438.	1.7	96

#	ARTICLE	IF	CITATIONS
73	ABVD in Older Patients With Early-Stage Hodgkin Lymphoma Treated Within the German Hodgkin Study Group HD10 and HD11 Trials. <i>Journal of Clinical Oncology</i> , 2013, 31, 1522-1529.	0.8	94
74	Prognostic value of KRAS mutations in stage III colon cancer: post hoc analysis of the PETACC8 phase III trial dataset. <i>Annals of Oncology</i> , 2014, 25, 2378-2385.	0.6	93
75	PET-guided omission of radiotherapy in early-stage unfavourable Hodgkin lymphoma (GHSG HD17): a multicentre, open-label, randomised, phase 3 trial. <i>Lancet Oncology</i> , The, 2021, 22, 223-234.	5.1	93
76	Bendamustine-bortezomib-dexamethasone is an active and well-tolerated regimen in patients with relapsed or refractory multiple myeloma. <i>Blood</i> , 2014, 123, 985-991.	0.6	92
77	Bleomycin in older early-stage favorable Hodgkin lymphoma patients: analysis of the German Hodgkin Study Group (GHSG) HD10 and HD13 trials. <i>Blood</i> , 2016, 127, 2189-2192.	0.6	92
78	Tamoxifen and Anastrozole As a Sequencing Strategy: A Randomized Controlled Trial in Postmenopausal Patients With Endocrine-Responsive Early Breast Cancer From the Austrian Breast and Colorectal Cancer Study Group. <i>Journal of Clinical Oncology</i> , 2012, 30, 722-728.	0.8	91
79	A prospective randomised phase III trial of adjuvant chemotherapy with 5-fluorouracil and leucovorin in patients with stage II colon cancer. <i>British Journal of Cancer</i> , 2007, 97, 1021-1027.	2.9	90
80	The Nationwide Austrian Aspergillus Registry: a prospective data collection on epidemiology, therapy and outcome of invasive mould infections in immunocompromised and/or immunosuppressed patients. <i>International Journal of Antimicrobial Agents</i> , 2010, 36, 531-536.	1.1	90
81	Leg ulcers associated with long-term hydroxyurea therapy. <i>Journal of the American Academy of Dermatology</i> , 1998, 39, 372-374.	0.6	89
82	Up-Regulation of Functional Chemokine Receptor CCR3 in Human Renal Cell Carcinoma. <i>Clinical Cancer Research</i> , 2005, 11, 2459-2465.	3.2	89
83	Bevacizumab plus chemotherapy continued beyond first progression in patients with metastatic colorectal cancer previously treated with bevacizumab plus chemotherapy: ML18147 study KRAS subgroup findings. <i>Annals of Oncology</i> , 2013, 24, 2342-2349.	0.6	89
84	Adjuvant Palbociclib for Early Breast Cancer: The PALLAS Trial Results (ABCSG-42/AFT-05/BIG-14-03). <i>Journal of Clinical Oncology</i> , 2022, 40, 282-293.	0.8	88
85	Measurable residual disease monitoring in acute myeloid leukemia with t(8;21)(q22;q22.1): results from the AML Study Group. <i>Blood</i> , 2019, 134, 1608-1618.	0.6	85
86	PKC ζ^2 is essential for the development of chronic lymphocytic leukemia in the TCL1 transgenic mouse model: validation of PKC ζ^2 as a therapeutic target in chronic lymphocytic leukemia. <i>Blood</i> , 2009, 113, 2791-2794.	0.6	84
87	Azacitidine in 302 patients with WHO-defined acute myeloid leukemia: results from the Austrian Azacitidine Registry of the AGMT-Study Group. <i>Annals of Hematology</i> , 2014, 93, 1825-1838.	0.8	84
88	Pathologic Complete Response With Six Compared With Three Cycles of Neoadjuvant Epirubicin Plus Docetaxel and Granulocyte Colony-Stimulating Factor in Operable Breast Cancer: Results of ABCSG-14. <i>Journal of Clinical Oncology</i> , 2007, 25, 2012-2018.	0.8	83
89	Development of CLL in the TCL1 transgenic mouse model is associated with severe skewing of the T-cell compartment homologous to human CLL. <i>Leukemia</i> , 2011, 25, 1452-1458.	3.3	83
90	Duration of Adjuvant Aromatase-Inhibitor Therapy in Postmenopausal Breast Cancer. <i>New England Journal of Medicine</i> , 2021, 385, 395-405.	13.9	82

#	ARTICLE	IF	CITATIONS
91	Cyclin D1 Expression in Breast Cancer Patients Receiving Adjuvant Tamoxifen-Based Therapy. <i>Clinical Cancer Research</i> , 2008, 14, 1767-1774.	3.2	81
92	<i>MDM2</i> SNP309 Is Associated With Poor Outcome in B-Cell Chronic Lymphocytic Leukemia. <i>Journal of Clinical Oncology</i> , 2008, 26, 2252-2257.	0.8	81
93	Adding dasatinib to intensive treatment in core-binding factor acute myeloid leukemia—results of the AMLSG 11-08 trial. <i>Leukemia</i> , 2018, 32, 1621-1630.	3.3	81
94	First-line panitumumab plus irinotecan/5-fluorouracil/leucovorin treatment in patients with metastatic colorectal cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2012, 138, 65-72.	1.2	79
95	Effect of Tailored Dose-Dense Chemotherapy vs Standard 3-Weekly Adjuvant Chemotherapy on Recurrence-Free Survival Among Women With High-Risk Early Breast Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2016, 316, 1888.	3.8	79
96	Genomic and Transcriptomic Analyses of Breast Cancer Primaries and Matched Metastases in AURORA, the Breast International Group (BIG) Molecular Screening Initiative. <i>Cancer Discovery</i> , 2021, 11, 2796-2811.	7.7	79
97	Pembrolizumab Alone or With Chemotherapy for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma in KEYNOTE-048: Subgroup Analysis by Programmed Death Ligand-1 Combined Positive Score. <i>Journal of Clinical Oncology</i> , 2022, 40, 2321-2332.	0.8	79
98	Circulating B-Cell Chronic Lymphocytic Leukemia Cells Display Impaired Migration to Lymph Nodes and Bone Marrow. <i>Cancer Research</i> , 2009, 69, 3121-3130.	0.4	78
99	Progression-free survival of early interim PET-positive patients with advanced stage Hodgkin's lymphoma treated with BEACOPPescalated alone or in combination with rituximab (HD18): an open-label, international, randomised phase 3 study by the German Hodgkin Study Group. <i>Lancet Oncology</i> , 2017, 18, 454-463.	5.1	78
100	Quality of life of patients with chronic lymphocytic leukemia: results of a longitudinal investigation over 14yr. <i>European Journal of Haematology</i> , 2004, 72, 381-389.	1.1	77
101	A phase 1 dose-escalation study on the safety, tolerability and activity of liposomal curcumin (Lipocurc,®) in patients with locally advanced or metastatic cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2018, 82, 695-706.	1.1	76
102	Rituximab maintenance for patients with aggressive B-cell lymphoma in first remission: results of the randomized NHL13 trial. <i>Haematologica</i> , 2015, 100, 955-963.	1.7	75
103	Landscape of HER2-low metastatic breast cancer (MBC): results from the Austrian AGMT_MBC-Registry. <i>Breast Cancer Research</i> , 2021, 23, 112.	2.2	75
104	Transendothelial Migration of Myeloma Cells Is Increased by Tumor Necrosis Factor (TNF)- α via TNF Receptor 2 and Autocrine Up-Regulation of MCP-1. <i>Clinical Cancer Research</i> , 2004, 10, 1901-1910.	3.2	73
105	Gemtuzumab Ozogamicin in <i>NPM1</i> -Mutated Acute Myeloid Leukemia: Early Results From the Prospective Randomized AMLSG 09-09 Phase III Study. <i>Journal of Clinical Oncology</i> , 2020, 38, 623-632.	0.8	73
106	CAR T-Cell Therapy in Hematological Malignancies. <i>International Journal of Molecular Sciences</i> , 2021, 22, 8996.	1.8	73
107	Valproic acid in combination with all-trans retinoic acid and intensive therapy for acute myeloid leukemia in older patients. <i>Blood</i> , 2014, 123, 4027-4036.	0.6	72
108	miR-16-5p Is a Stably-Expressed Housekeeping MicroRNA in Breast Cancer Tissues from Primary Tumors and from Metastatic Sites. <i>International Journal of Molecular Sciences</i> , 2016, 17, 156.	1.8	71

#	ARTICLE	IF	CITATIONS
109	Impact of antibiotic treatment on immune-checkpoint blockade efficacy in advanced non-squamous non-small cell lung cancer. <i>Oncotarget</i> , 2018, 9, 16512-16520.	0.8	71
110	Modulation of Apo-1/Fas (CD95)-induced programmed cell death in myeloma cells by interferon- γ . <i>European Journal of Immunology</i> , 1996, 26, 3119-3126.	1.6	70
111	Cancer-Related Fatigue in Patients With and Survivors of Hodgkin Lymphoma: The Impact on Treatment Outcome and Social Reintegration. <i>Journal of Clinical Oncology</i> , 2016, 34, 4329-4337.	0.8	70
112	Randomized Phase II Study of Bortezomib, Thalidomide, and Dexamethasone With or Without Cyclophosphamide As Induction Therapy in Previously Untreated Multiple Myeloma. <i>Journal of Clinical Oncology</i> , 2013, 31, 247-255.	0.8	69
113	A modified scoring of the <sc>NCCN</sc>â€œ<sc>IPI</sc> is more accurate in the elderly and is improved by albumin and β_2 -microglobulin. <i>British Journal of Haematology</i> , 2015, 168, 239-245.	1.2	69
114	The genomic expression test EndoPredict is a prognostic tool for identifying risk of local recurrence in postmenopausal endocrine receptor-positive, her2neu-negative breast cancer patients randomised within the prospective ABCSG 8 trial. <i>British Journal of Cancer</i> , 2015, 112, 1405-1410.	2.9	68
115	Randomized Phase III Study of FOLFOX Alone or With Pegilodecakin as Second-Line Therapy in Patients With Metastatic Pancreatic Cancer That Progressed After Gemcitabine (SEQUOIA). <i>Journal of Clinical Oncology</i> , 2021, 39, 1108-1118.	0.8	67
116	Urticaria Pigmentosa: A Clinical, Hematopathologic, and Serologic Study of 30 Adults. <i>American Journal of Clinical Pathology</i> , 1998, 109, 279-285.	0.4	66
117	Efficacy and safety of dabrafenib (D) and trametinib (T) in patients (pts) with <i>BRAF</i> V600Eâ€œmutated biliary tract cancer (BTC): A cohort of the ROAR basket trial.. <i>Journal of Clinical Oncology</i> , 2019, 37, 187-187.	0.8	66
118	Cardiotoxicity with rituximab, cyclophosphamide, non-pegylated liposomal doxorubicin, vincristine and prednisolone compared to rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone in frontline treatment of patients with diffuse large B-cell lymphoma. <i>European Journal of Cancer</i> , 2016, 58, 112-121.	1.3	64
119	Olaptesed pegol, an anti-CXCL12/SDF-1 Spiegelmer, alone and with bortezomibâ€œdexamethasone in relapsed/refractory multiple myeloma: a Phase IIa Study. <i>Leukemia</i> , 2017, 31, 997-1000.	3.3	64
120	Inhibition of G1I, but not Smoothened, induces apoptosis in chronic lymphocytic leukemia cells. <i>Oncogene</i> , 2010, 29, 4885-4895.	2.6	63
121	Digging deep into â€œdirtyâ€œdrugs â€œmodulation of the methylation machinery. <i>Drug Metabolism Reviews</i> , 2015, 47, 252-279.	1.5	63
122	The double-edged sword of (re)expression of genes by hypomethylating agents: from viral mimicry to exploitation as priming agents for targeted immune checkpoint modulation. <i>Cell Communication and Signaling</i> , 2017, 15, 13.	2.7	63
123	Inhibition of histone deacetylase activity enhances Fas receptor-mediated apoptosis in leukemic lymphoblasts. <i>Cell Death and Differentiation</i> , 2001, 8, 1014-1021.	5.0	62
124	Epirubicin and docetaxel with or without capecitabine as neoadjuvant treatment for early breast cancer: final results of a randomized phase III study (ABCSG-24). <i>Annals of Oncology</i> , 2014, 25, 366-371.	0.6	62
125	<i>DPYD</i> Genotyping to Predict Adverse Events Following Treatment With Fluorouracil-Based Adjuvant Chemotherapy in Patients With Stage III Colon Cancer. <i>JAMA Oncology</i> , 2016, 2, 655.	3.4	62
126	Tiam1/Rac1 signals contribute to the proliferation and chemoresistance, but not motility, of chronic lymphocytic leukemia cells. <i>Blood</i> , 2014, 123, 2181-2188.	0.6	61

#	ARTICLE	IF	CITATIONS
127	Azacitidine in CMML: Matched-pair analyses of daily-life patients reveal modest effects on clinical course and survival. <i>Leukemia Research</i> , 2014, 38, 475-483.	0.4	59
128	Single-agent purine analogues for the treatment of chronic lymphocytic leukaemia: A systematic review and meta-analysis. <i>Cancer Treatment Reviews</i> , 2006, 32, 377-389.	3.4	58
129	Liposomal cytarabine is effective and tolerable in the treatment of central nervous system relapse of acute lymphoblastic leukemia and very aggressive lymphoma. <i>Haematologica</i> , 2011, 96, 238-244.	1.7	57
130	The predictive impact of body mass index on the efficacy of extended adjuvant endocrine treatment with anastrozole in postmenopausal patients with breast cancer: an analysis of the randomised ABCSG-6a trial. <i>British Journal of Cancer</i> , 2013, 109, 589-596.	2.9	57
131	Azacitidine in patients with WHO-defined AML – Results of 155 patients from the Austrian Azacitidine Registry of the AGMT-Study Group. <i>Journal of Hematology and Oncology</i> , 2013, 6, 32.	6.9	56
132	Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer (TURANDOT): primary endpoint results of a randomised, open-label, non-inferiority, phase 3 trial. <i>Lancet Oncology</i> , The, 2016, 17, 1230-1239.	5.1	55
133	TIGIT expressing CD4+T cells represent a tumor-supportive T cell subset in chronic lymphocytic leukemia. <i>Oncolmmunology</i> , 2018, 7, e1371399.	2.1	55
134	Utility of PCR in Diagnosis of Invasive Fungal Infections: Real-Life Data from a Multicenter Study. <i>Journal of Clinical Microbiology</i> , 2013, 51, 863-868.	1.8	54
135	Prediction of Distant Recurrence Using EndoPredict Among Women with ER+, HER2 ⁺ Node-Positive and Node-Negative Breast Cancer Treated with Endocrine Therapy Only. <i>Clinical Cancer Research</i> , 2019, 25, 3865-3872.	3.2	54
136	First-line treatment of chronic lymphocytic leukemia with ibrutinib plus obinutuzumab <i>> versus <i>> chlorambucil plus obinutuzumab: final analysis of the randomized, phase III iLLUMINATE trial. <i>Haematologica</i> , 2022, 107, 2108-2120.	1.7	53
137	Neoadjuvant Chemotherapy and Targeted Therapy in Breast Cancer: Past, Present, and Future. <i>Journal of Oncology</i> , 2013, 2013, 1-12.	0.6	52
138	Alemtuzumab plus CHOP versus CHOP in elderly patients with peripheral T-cell lymphoma: the DSHNHL2006-1B/ACT-2 trial. <i>Leukemia</i> , 2021, 35, 143-155.	3.3	52
139	Rapidly Alternating COPP/ABV/IMEP Is Not Superior to Conventional Alternating COPP/ABVD in Combination With Extended-Field Radiotherapy in Intermediate-Stage Hodgkin's Lymphoma: Final Results of the German Hodgkin's Lymphoma Study Group Trial HD5. <i>Journal of Clinical Oncology</i> , 2002, 20, 476-484.	0.8	51
140	Regulatory T cells predict the time to initial treatment in early stage chronic lymphocytic leukemia. <i>Cancer</i> , 2011, 117, 2163-2169.	2.0	51
141	Canonical and Noncanonical Hedgehog/GLI Signaling in Hematological Malignancies. <i>Vitamins and Hormones</i> , 2012, 88, 25-54.	0.7	51
142	Hedgehog/GLI and PI3K signaling in the initiation and maintenance of chronic lymphocytic leukemia. <i>Oncogene</i> , 2015, 34, 5341-5351.	2.6	51
143	A phase 2 study of rituximab plus lenalidomide for mucosa-associated lymphoid tissue lymphoma. <i>Blood</i> , 2017, 129, 383-385.	0.6	51
144	Lenalidomide in combination with vorinostat and dexamethasone for the treatment of relapsed/refractory peripheral T cell lymphoma (PTCL): report of a phase I/II trial. <i>Annals of Hematology</i> , 2014, 93, 459-462.	0.8	50

#	ARTICLE	IF	CITATIONS
145	Azacitidine frontline therapy for unfit acute myeloid leukemia patients: Clinical use and outcome prediction. <i>Leukemia Research</i> , 2015, 39, 296-306.	0.4	50
146	Synergistic action of protein kinase C δ and calcineurin is sufficient for Fas ligand expression and induction of a crmA-sensitive apoptosis pathway in Jurkat T cells. <i>European Journal of Immunology</i> , 1999, 29, 3549-3561.	1.6	49
147	Tetrocarcin-A α -induced ER stress mediates apoptosis in B-CLL cells via a Bcl-2 α -independent pathway. <i>Blood</i> , 2003, 101, 4561-4568.	0.6	49
148	Prognostic Value of Number of Removed Lymph Nodes, Number of Involved Lymph Nodes, and Lymph Node Ratio in 7502 Breast Cancer Patients Enrolled onto Trials of the Austrian Breast and Colorectal Cancer Study Group (ABCSCG). <i>Annals of Surgical Oncology</i> , 2012, 19, 1808-1817.	0.7	49
149	Oncogenic role of miR-155 in anaplastic large cell lymphoma lacking the t(2;5) translocation. <i>Journal of Pathology</i> , 2015, 236, 445-456.	2.1	49
150	Increased body mass index is associated with improved overall survival in diffuse large B-cell lymphoma. <i>Annals of Oncology</i> , 2014, 25, 171-176.	0.6	48
151	C-reactive protein level is a prognostic indicator for survival and improves the predictive ability of the R-IPi score in diffuse large B-cell lymphoma patients. <i>British Journal of Cancer</i> , 2014, 111, 55-60.	2.9	48
152	Stressful death of T α -ALL tumor cells following treatment with the antitumor agent Tetrocarcin α . <i>FASEB Journal</i> , 2002, 16, 1295-1297.	0.2	46
153	Treatment of advanced Hodgkin α 's disease with COPP/ABV/IMEP versus COPP/ABVD and consolidating radiotherapy: final results of the German Hodgkin α 's Lymphoma Study Group HD6 trial. <i>Annals of Oncology</i> , 2004, 15, 276-282.	0.6	45
154	Azacitidine for Front-Line Therapy of Patients with AML: Reproducible Efficacy Established by Direct Comparison of International Phase 3 Trial Data with Registry Data from the Austrian Azacitidine Registry of the AGMT Study Group. <i>International Journal of Molecular Sciences</i> , 2017, 18, 415.	1.8	45
155	Targeted therapy in advanced metastatic colorectal cancer: Current concepts and perspectives. <i>World Journal of Gastroenterology</i> , 2014, 20, 6102.	1.4	45
156	Analysis of Bcl-2 Protein Expression in Chronic Lymphocytic Leukemia. <i>American Journal of Clinical Pathology</i> , 2000, 113, 219-229.	0.4	44
157	Molecular responses and chromosomal aberrations in patients with polycythemia vera treated with peg α -proline α -interferon alpha α 2b. <i>American Journal of Hematology</i> , 2015, 90, 288-294.	2.0	44
158	Radiologic complete response (rCR) in contrast-enhanced magnetic resonance imaging (CE-MRI) after neoadjuvant chemotherapy for early breast cancer predicts recurrence-free survival but not pathologic complete response (pCR). <i>Breast Cancer Research</i> , 2019, 21, 19.	2.2	44
159	Next Generation Sequencing in AML α —On the Way to Becoming a New Standard for Treatment Initiation and/or Modulation?. <i>Cancers</i> , 2019, 11, 252.	1.7	44
160	Differential Bone Marrow Homing Capacity of VLA-4 and CD38 High Expressing Chronic Lymphocytic Leukemia Cells. <i>PLoS ONE</i> , 2011, 6, e23758.	1.1	43
161	A monoclonal antibody directed against the human intercellular adhesion molecule (ICAM-1) modulates the release of tumor necrosis factor- α , interferon- γ and interleukin 1. <i>European Journal of Immunology</i> , 1990, 20, 2591-2596.	1.6	42
162	A role of TRAIL in killing osteoblasts by myeloma cells. <i>FASEB Journal</i> , 2006, 20, 759-761.	0.2	42

#	ARTICLE	IF	CITATIONS
163	A phase I/II study of bortezomib and capecitabine in patients with metastatic breast cancer previously treated with taxanes and/or anthracyclines. <i>Annals of Oncology</i> , 2008, 19, 871-876.	0.6	42
164	The involvement of the fractalkine receptor in the transmigration of neuroblastoma cells through bone-marrow endothelial cells. <i>Cancer Letters</i> , 2009, 273, 127-139.	3.2	42
165	Rituximab maintenance versus observation alone in patients with chronic lymphocytic leukaemia who respond to first-line or second-line rituximab-containing chemoimmunotherapy: final results of the AGMT CLL-8a Maintenance randomised trial. <i>Lancet Haematology</i> , 2016, 3, e317-e329.	2.2	42
166	Routine clinical use of alemtuzumab in patients with heavily pretreated B-cell chronic lymphocytic leukemia. <i>Cancer</i> , 2006, 107, 2408-2416.	2.0	41
167	The pathogenic relevance of the prognostic markers CD38 and CD49d in chronic lymphocytic leukemia. <i>Annals of Hematology</i> , 2014, 93, 361-374.	0.8	41
168	Baseline Absolute Lymphocyte Count and ECOG Performance Score Are Associated with Survival in Advanced Non-Small Cell Lung Cancer Undergoing PD-1/PD-L1 Blockade. <i>Journal of Clinical Medicine</i> , 2019, 8, 1014.	1.0	41
169	PLZF/ZBTB16, a glucocorticoid response gene in acute lymphoblastic leukemia, interferes with glucocorticoid-induced apoptosis. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2010, 120, 218-227.	1.2	40
170	Expression of ApoA1/Fas (CD95), Bcl2, Bax and Bclx in myeloma cell lines: relationship between responsiveness to anti-Fas mab and p53 functional status. <i>British Journal of Haematology</i> , 1997, 97, 418-428.	1.2	39
171	Histone deacetylase inhibitors potently repress CXCR4 chemokine receptor expression and function in acute lymphoblastic leukaemia. <i>British Journal of Haematology</i> , 2002, 119, 965-969.	1.2	39
172	Mesenchymal Stem and Progenitor Cells in Normal and Dysplastic Hematopoiesis—Masters of Survival and Clonality?. <i>International Journal of Molecular Sciences</i> , 2016, 17, 1009.	1.8	39
173	Plitidepsin: a potential new treatment for relapsed/refractory multiple myeloma. <i>Future Oncology</i> , 2019, 15, 109-120.	1.1	39
174	Randomized phase III study (ADMYRE) of plitidepsin in combination with dexamethasone vs. dexamethasone alone in patients with relapsed/refractory multiple myeloma. <i>Annals of Hematology</i> , 2019, 98, 2139-2150.	0.8	39
175	Two Years Rituximab Maintenance Vs. Observation after First Line Treatment with Bendamustine Plus Rituximab (B-R) in Patients with Waldenström's Macroglobulinemia (MW): Results of a Prospective, Randomized, Multicenter Phase 3 Study (the StiL NHL7-2008 MAINTAIN trial). <i>Blood</i> , 2019, 134, 343-343.	0.6	39
176	Clinical outcome with bevacizumab in patients with recurrent high-grade glioma treated outside clinical trials. <i>Acta Oncologica</i> , 2011, 50, 630-635.	0.8	38
177	Cytomegalovirus reactivation and its clinical impact in patients with solid tumors. <i>Infectious Agents and Cancer</i> , 2015, 10, 45.	1.2	38
178	Chronic lymphocytic leukaemia induces an exhausted T cell phenotype in the <scp>TCL</scp>1 transgenic mouse model. <i>British Journal of Haematology</i> , 2015, 170, 515-522.	1.2	38
179	Longer Failure-Free Survival Interval of Epstein-Barr Virus-Associated Classical Hodgkin's Lymphoma: A Single-Institution Study. <i>Modern Pathology</i> , 2003, 16, 566-573.	2.9	37
180	Tumour-immune cell interactions modulated by chemokines. <i>Expert Opinion on Biological Therapy</i> , 2008, 8, 269-290.	1.4	37

#	ARTICLE	IF	CITATIONS
181	Mosunetuzumab, a Novel CD20/CD3 Bispecific Antibody, in Combination with CHOP Confers High Response Rates in Patients with Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2020, 136, 37-38.	0.6	37
182	Multidimensional scaling as a tool for analysing quality of life data. <i>Quality of Life Research</i> , 2002, 11, 223-233.	1.5	36
183	Neoadjuvant bevacizumab, docetaxel and capecitabine combination therapy for HER2/neu-negative invasive breast cancer: Efficacy and safety in a phase II pilot study. <i>European Journal of Surgical Oncology</i> , 2009, 35, 1048-1054.	0.5	36
184	Antimyeloma activity of the sesquiterpene lactone crnicin: impact on Pim-2 kinase as a novel therapeutic target. <i>Journal of Molecular Medicine</i> , 2012, 90, 681-693.	1.7	36
185	Rituximab plus subcutaneous cladribine in patients with extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue: a phase II study by the Arbeitsgemeinschaft Medikamentöse Tumortherapie. <i>Haematologica</i> , 2013, 98, 264-268.	1.7	36
186	Female gender may predict response to FOLFIRINOX in patients with unresectable pancreatic cancer: A single institution retrospective review. <i>International Journal of Oncology</i> , 2014, 44, 319-326.	1.4	36
187	Azacitidine front-line in 339 patients with myelodysplastic syndromes and acute myeloid leukaemia: comparison of French-American-British and World Health Organization classifications. <i>Journal of Hematology and Oncology</i> , 2016, 9, 39.	6.9	36
188	The interleukin 1 β -converting enzyme inhibitor CrmA prevents Apo1/Fas- but not glucocorticoid-induced poly(ADP-ribose) polymerase cleavage and apoptosis in lymphoblastic leukemia cells. <i>FEBS Letters</i> , 1997, 402, 36-40.	1.3	35
189	IL-4 inhibits the TNF- α induced proliferation of renal cell carcinoma (RCC) and cooperates with TNF- α to induce apoptotic and cytokine responses by RCC: implications for antitumor immune responses. <i>Cancer Immunology, Immunotherapy</i> , 2006, 55, 1228-1237.	2.0	35
190	Chemotherapy-induced augmentation of T cells expressing inhibitory receptors is reversed by treatment with lenalidomide in chronic lymphocytic leukemia. <i>Haematologica</i> , 2014, 99, 67-69.	1.7	35
191	Clonal evolution in relapsed and refractory diffuse large B-cell lymphoma is characterized by high dynamics of subclones. <i>Oncotarget</i> , 2016, 7, 51494-51502.	0.8	35
192	Vinorelbine+gemcitabine in advanced non-small-cell lung cancer (NSCLC): An AASLC phase II trial. <i>Annals of Oncology</i> , 2000, 11, 993-998.	0.6	34
193	Exemestane as primary systemic treatment for hormone receptor positive post-menopausal breast cancer patients: a phase II trial of the Austrian Breast and Colorectal Cancer Study Group (ABCSG-17). <i>Breast Cancer Research and Treatment</i> , 2008, 112, 203-213.	1.1	34
194	CD40-Mediated Activation of Chronic Lymphocytic Leukemia Cells Promotes Their CD44-Dependent Adhesion to Hyaluronan and Restricts CCL21-Induced Motility. <i>Cancer Research</i> , 2013, 73, 561-570.	0.4	34
195	Reactivation of dormant anti-tumor immunity – a clinical perspective of therapeutic immune checkpoint modulation. <i>Cell Communication and Signaling</i> , 2017, 15, 5.	2.7	34
196	Elevated levels of soluble CD44 are associated with advanced disease and in vitro proliferation of neoplastic lymphocytes in B-cell chronic lymphocytic leukaemia. <i>Leukemia Research</i> , 2004, 28, 1043-1051.	0.4	33
197	The AST/ALT (De Ritis) ratio predicts clinical outcome in patients with pancreatic cancer treated with first-line nab-paclitaxel and gemcitabine: <i>post hoc</i> analysis of an Austrian multicenter, noninterventional study. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883591990087.	1.4	33
198	Prognostic and Predictive Factors in Advanced Head and Neck Squamous Cell Carcinoma. <i>International Journal of Molecular Sciences</i> , 2021, 22, 4981.	1.8	33

#	ARTICLE	IF	CITATIONS
199	Viral infections and their management in patients with chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2013, 54, 1602-1613.	0.6	32
200	IOERT as anticipated tumor bed boost during breast-conserving surgery after neoadjuvant chemotherapy in locally advanced breast cancer—Results of a case series after 5-year follow-up. <i>International Journal of Cancer</i> , 2015, 136, 1193-1201.	2.3	32
201	Outcomes of patients with chronic myelomonocytic leukaemia treated with non-curative therapies: a retrospective cohort study. <i>Lancet Haematology</i> , 2021, 8, e135-e148.	2.2	32
202	Midostaurin in Combination with Intensive Induction and As Single Agent Maintenance Therapy after Consolidation Therapy with Allogeneic Hematopoietic Stem Cell Transplantation or High-Dose Cytarabine (NCT01477606). <i>Blood</i> , 2015, 126, 322-322.	0.6	32
203	Expression levels of CD38 in T cells predict course of disease in male patients with B-chronic lymphocytic leukemia. <i>Blood</i> , 2006, 108, 2950-2956.	0.6	31
204	Modulation of plasma complement by the initial dose of epirubicin/docetaxel therapy in breast cancer and its predictive value. <i>British Journal of Cancer</i> , 2010, 103, 1201-1208.	2.9	31
205	Fludarabine modulates composition and function of the T cell pool in patients with chronic lymphocytic leukaemia. <i>Cancer Immunology, Immunotherapy</i> , 2011, 60, 75-85.	2.0	31
206	Combination Strategies for Immune-Checkpoint Blockade and Response Prediction by Artificial Intelligence. <i>International Journal of Molecular Sciences</i> , 2020, 21, 2856.	1.8	31
207	Bevacizumab (BEV) plus chemotherapy (CT) continued beyond first progression in patients with metastatic colorectal cancer (mCRC) previously treated with BEV plus CT: Results of a randomized phase III intergroup study (TML study).. <i>Journal of Clinical Oncology</i> , 2012, 30, CRA3503-CRA3503.	0.8	31
208	Interferon-alpha-2C and LD ara-C for the treatment of patients with CML: Results of the austrian multicenter phase II study. <i>Leukemia Research</i> , 1997, 21, 75-80.	0.4	30
209	Purine Antagonists for Chronic Lymphocytic Leukaemia. <i>The Cochrane Library</i> , 2006, , CD004270.	1.5	30
210	Difference in the Relative Distribution of CD4+ T-cell Subsets in B-CLL With Mutated and Unmutated Immunoglobulin (Ig) VH Genes. <i>Journal of Immunotherapy</i> , 2009, 32, 302-309.	1.2	30
211	Skin toxicity and quality of life in patients with metastatic colorectal cancer during first-line panitumumab plus FOLFIRI treatment in a single-arm phase II study. <i>BMC Cancer</i> , 2012, 12, 438.	1.1	30
212	Splenectomy versus medical treatment for idiopathic thrombocytopenic purpura. <i>American Journal of Surgery</i> , 2002, 184, 606-609.	0.9	29
213	Extensive organizing pneumonia during chemo-immunotherapy containing rituximab and G-CSF in a patient with diffuse large B-cell lymphoma: Case report and review of the literature. <i>Leukemia and Lymphoma</i> , 2006, 47, 1683-1685.	0.6	29
214	Targeting proliferation of chronic lymphocytic leukemia (CLL) cells through KCa3.1 blockade. <i>Leukemia</i> , 2014, 28, 954-958.	3.3	29
215	The significance of pretreatment anemia in the era of IPI and NCCN-IPI prognostic risk assessment tools: a dual-center study in diffuse large B-cell lymphoma patients. <i>European Journal of Haematology</i> , 2015, 95, 538-544.	1.1	29
216	The EndoPredict score predicts response to neoadjuvant chemotherapy and neoendocrine therapy in hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer patients from the ABCSG-34 trial. <i>European Journal of Cancer</i> , 2020, 134, 99-106.	1.3	29

#	ARTICLE	IF	CITATIONS
217	CD44 loss of function sensitizes AML cells to the BCL-2 inhibitor venetoclax by decreasing CXCL12-driven survival cues. <i>Blood</i> , 2021, 138, 1067-1080.	0.6	29
218	Gemcitabine/nab-Paclitaxel versus FOLFIRINOX for palliative first-line treatment of advanced pancreatic cancer: A propensity score analysis. <i>European Journal of Cancer</i> , 2021, 151, 3-13.	1.3	29
219	On the Role and Significance of Fas (Apo-1/CD95) Ligand (FasL) Expression in Immune Privileged Tissues and Cancer Cells Using Multiple Myeloma as a Model*. <i>Leukemia and Lymphoma</i> , 1998, 31, 477-490.	0.6	28
220	The potential risk of neoadjuvant chemotherapy in breast cancer patients—results from a prospective randomized trial of the Austrian Breast and Colorectal Cancer Study Group (ABCSG-07). <i>Breast Cancer Research and Treatment</i> , 2008, 112, 309-316.	1.1	28
221	Oxaliplatin in Combination with 5-Fluorouracil/Leucovorin or Capecitabine in Elderly Patients with Metastatic Colorectal Cancer. <i>Clinical Colorectal Cancer</i> , 2008, 7, 60-64.	1.0	28
222	Anemia Is a Significant Prognostic Factor in Local Relapse-Free Survival of Premenopausal Primary Breast Cancer Patients Receiving Adjuvant Cyclophosphamide/Methotrexate/5-Fluorouracil Chemotherapy. <i>Clinical Cancer Research</i> , 2008, 14, 2082-2087.	3.2	28
223	Independent Prognostic Value of Serum Markers in Diffuse Large B-Cell Lymphoma in the Era of the NCCN-IPI. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2015, 13, 1501-1508.	2.3	28
224	Combined CXCR3/CXCR4 measurements are of high prognostic value in chronic lymphocytic leukemia due to negative co-operativity of the receptors. <i>Haematologica</i> , 2016, 101, e99-e102.	1.7	28
225	Improvement of quality of life and psychological distress after inpatient cancer rehabilitation. <i>Wiener Klinische Wochenschrift</i> , 2017, 129, 692-701.	1.0	28
226	The multiple myeloma treatment landscape: international guideline recommendations and clinical practice in Europe. <i>Expert Review of Hematology</i> , 2018, 11, 219-237.	1.0	28
227	DNA Methylation Signatures Predicting Bevacizumab Efficacy in Metastatic Breast Cancer. <i>Theranostics</i> , 2018, 8, 2278-2288.	4.6	28
228	Health-Related Quality of Life in Patients With Hodgkin Lymphoma: A Longitudinal Analysis of the German Hodgkin Study Group. <i>Journal of Clinical Oncology</i> , 2020, 38, 2839-2848.	0.8	28
229	PET-guided eBEACOPP treatment of advanced-stage Hodgkin lymphoma (HD18): follow-up analysis of an international, open-label, randomised, phase 3 trial. <i>Lancet Haematology</i> , 2021, 8, e398-e409.	2.2	28
230	Novel Therapeutic Options in Anaplastic Large Cell Lymphoma: Molecular Targets and Immunological Tools. <i>Molecular Cancer Therapeutics</i> , 2011, 10, 1127-1136.	1.9	27
231	Lipid profiles for etravirine versus efavirenz in treatment-naive patients in the randomized, double-blind SENSE trial. <i>Journal of Antimicrobial Chemotherapy</i> , 2012, 67, 685-690.	1.3	27
232	NCCN-IPI score-independent prognostic potential of pretreatment uric acid levels for clinical outcome of diffuse large B-cell lymphoma patients. <i>British Journal of Cancer</i> , 2016, 115, 1264-1272.	2.9	27
233	Hypertension as a predictive marker for bevacizumab in metastatic breast cancer: results from a retrospective matched-pair analysis. <i>Anticancer Research</i> , 2014, 34, 227-33.	0.5	27
234	Preoperative treatment with capecitabine, cetuximab and radiotherapy for primary locally advanced rectal cancer—a phase II clinical trial. <i>Anticancer Research</i> , 2014, 34, 6767-73.	0.5	27

#	ARTICLE	IF	CITATIONS
235	A randomized study comparing interferon (IFN α) plus low-dose cytarabine and interferon plus hydroxyurea (HU) in early chronic-phase chronic myeloid leukemia (CML). <i>Leukemia Research</i> , 2003, 27, 405-411.	0.4	26
236	Tracking death dealing by Fas and TRAIL in lymphatic neoplastic disorders: pathways, targets, and therapeutic tools. <i>Journal of Leukocyte Biology</i> , 2003, 74, 311-330.	1.5	26
237	Low p27 Expression Predicts Early Relapse and Death in Postmenopausal Hormone Receptor-Positive Breast Cancer Patients Receiving Adjuvant Tamoxifen Therapy. <i>Clinical Cancer Research</i> , 2009, 15, 5888-5894.	3.2	26
238	Raltegravir in pregnancy: a case series presentation. <i>International Journal of STD and AIDS</i> , 2011, 22, 358-360.	0.5	26
239	Selecting first-line bevacizumab-containing therapy for advanced breast cancer: TURANDOT risk factor analyses. <i>British Journal of Cancer</i> , 2014, 111, 2051-2057.	2.9	26
240	CD18 (ITGB2) expression in chronic lymphocytic leukaemia is regulated by DNA methylation-dependent and -independent mechanisms. <i>British Journal of Haematology</i> , 2015, 169, 286-289.	1.2	26
241	Bortezomib, thalidomide and dexamethasone, with or without cyclophosphamide, for patients with previously untreated multiple myeloma: 5-year follow-up. <i>British Journal of Haematology</i> , 2015, 171, 344-354.	1.2	26
242	Lenalidomide and dexamethasone for acute light chain-induced renal failure: a phase II study. <i>Haematologica</i> , 2015, 100, 385-391.	1.7	26
243	Endocrine therapy with or without whole breast irradiation in low-risk breast cancer patients after breast-conserving surgery: 10-year results of the Austrian Breast and Colorectal Cancer Study Group 8A trial. <i>European Journal of Cancer</i> , 2020, 127, 12-20.	1.3	26
244	Azacitidine in Patients with Acute Myeloid Leukemia: Impact of Intermediate-Risk Vs High-Risk Cytogenetics on Patient Outcomes. <i>Blood</i> , 2014, 124, 955-955.	0.6	26
245	IMMUNOHISTOLOGY FOR QUANTIFICATION OF NORMAL BONE MARROW LYMPHOCYTE SUBSETS. <i>British Journal of Haematology</i> , 1989, 73, 576-577.	1.2	25
246	Epstein-Barr virus-associated extranodal NK/T-cell lymphoma, nasal type of the hypopharynx, in a renal allograft recipient: Case report and review of literature. <i>Human Pathology</i> , 2001, 32, 1264-1268.	1.1	25
247	The Role of Soluble CD23 in Distinguishing Stable and Progressive Forms of B-chronic Lymphocytic Leukemia. <i>Leukemia and Lymphoma</i> , 2002, 43, 549-554.	0.6	25
248	Efficacy of tamoxifen \pm aminoglutethimide in normal weight and overweight postmenopausal patients with hormone receptor-positive breast cancer: an analysis of 1509 patients of the ABCSG-06 trial. <i>British Journal of Cancer</i> , 2013, 108, 1408-1414.	2.9	25
249	Clonal evolution and heterogeneity in metastatic head and neck cancer—An analysis of the Austrian Study Group of Medical Tumour Therapy study group. <i>European Journal of Cancer</i> , 2018, 93, 69-78.	1.3	25
250	Effect of remdesivir on viral dynamics in COVID-19 hospitalized patients: a modelling analysis of the randomized, controlled, open-label DisCoVeRy trial. <i>Journal of Antimicrobial Chemotherapy</i> , 2022, 77, 1404-1412.	1.3	25
251	Arsenic trioxide induces apoptosis preferentially in B-CLL cells of patients with unfavourable prognostic factors including del(17p13). <i>Journal of Molecular Medicine</i> , 2008, 86, 541-552.	1.7	24
252	Modifying Akt Signaling in B-Cell Chronic Lymphocytic Leukemia Cells. <i>Cancer Research</i> , 2010, 70, 7336-7344.	0.4	24

#	ARTICLE	IF	CITATIONS
253	Mimicking the microenvironment in chronic lymphocytic leukaemia " where does the journey go?. British Journal of Haematology, 2013, 160, 711-714.	1.2	24
254	Efficacy and safety of the therapeutic cancer vaccine tecemotide (L-BLP25) in early breast cancer: Results from a prospective, randomised, neoadjuvant phase II study (ABCSC 34). European Journal of Cancer, 2020, 132, 43-52.	1.3	24
255	Combined Modality Treatment of Two or Four Cycles of ABVD Followed by Involved Field Radiotherapy in the Treatment of Patients with Early Stage Hodgkin's Lymphoma: Update Interim Analysis of the Randomised HD10 Study of the German Hodgkin Study Group (GHSG).. Blood, 2005, 106, 2673-2673.	0.6	24
256	Constituents of autocrine IL-6 loops in myeloma cell lines and their targeting for suppression of neoplastic growth by antibody strategies. , 1996, 65, 498-505.		23
257	Randomized open label phase III trial of CEOP/IMVP-Dexa alternating chemotherapy and filgrastim versus CEOP/IMVP-Dexa alternating chemotherapy for aggressive non-Hodgkin's lymphoma (NHL). A multi- center trial by the Austrian Working Group For Medical Tumor Therapy. Annals of Hematology, 1997. 75. 135-140.	0.8	23
258	Preoperative Oxaliplatin, Capecitabine, and External Beam Radiotherapy in Patients with Newly Diagnosed, Primary Operable, cT3NxM0, Low Rectal Cancer. Strahlentherapie Und Onkologie, 2011, 187, 100-107.	1.0	23
259	Induction chemotherapy with docetaxel, cisplatin and 5-fluorouracil followed by radiotherapy with cetuximab for locally advanced squamous cell carcinoma of the head and neck. European Journal of Cancer, 2013, 49, 352-359.	1.3	23
260	Real life experience with frontline azacitidine in a large series of older adults with acute myeloid leukemia stratified by MRC/LRF score: results from the expanded international E-ALMA series (E-ALMA+). Leukemia and Lymphoma, 2018, 59, 1113-1120.	0.6	23
261	Supervised versus autonomous exercise training in breast cancer patients: A multicenter randomized clinical trial. Cancer Medicine, 2018, 7, 5962-5972.	1.3	23
262	Cure in metastatic breast cancer. Memo - Magazine of European Medical Oncology, 2018, 11, 172-179.	0.3	23
263	BIRC3 Expression Predicts CLL Progression and Defines Treatment Sensitivity via Enhanced NF- κ B Nuclear Translocation. Clinical Cancer Research, 2019, 25, 1901-1912.	3.2	23
264	Adjuvant denosumab in early breast cancer: Disease-free survival analysis of 3,425 postmenopausal patients in the ABCSC-18 trial.. Journal of Clinical Oncology, 2018, 36, 500-500.	0.8	23
265	2-Fluorodeoxycytidine (Gemcitabine) Induces Apoptosis in Myeloma Cell Lines Resistant to Steroids and 2-Chlorodeoxyadenosine (2CdA). Stem Cells, 1996, 14, 351-362.	1.4	22
266	AID induces intraclonal diversity and genomic damage in CD86 + chronic lymphocytic leukemia cells. European Journal of Immunology, 2014, 44, 3747-3757.	1.6	22
267	Sensitive testing of plasma HIV-1 RNA and Sanger sequencing of cellular HIV-1 DNA for the detection of drug resistance prior to starting first-line antiretroviral therapy with etravirine or efavirenz. Journal of Antimicrobial Chemotherapy, 2014, 69, 1090-1097.	1.3	22
268	Cost-Effectiveness Analysis of Prognostic Gene Expression Signature-Based Stratification of Early Breast Cancer Patients. Pharmacoeconomics, 2015, 33, 179-190.	1.7	22
269	Update on squamous cell carcinoma of the head and neck. Memo - Magazine of European Medical Oncology, 2017, 10, 220-223.	0.3	22
270	Exome sequencing of the TCL1 mouse model for CLL reveals genetic heterogeneity and dynamics during disease development. Leukemia, 2019, 33, 957-968.	3.3	22

#	ARTICLE	IF	CITATIONS
271	Prognostic Value of EndoPredict in Women with Hormone Receptor-Positive, HER2-Negative Invasive Lobular Breast Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 4682-4687.	3.2	22
272	CD44 engagement enhances acute myeloid leukemia cell adhesion to the bone marrow microenvironment by increasing VLA-4 avidity. <i>Haematologica</i> , 2021, 106, 2102-2113.	1.7	22
273	Is it time to consider neoadjuvant treatment as the standard of care in oesophageal cancer?. <i>Lancet Oncology</i> , The, 2007, 8, 189-190.	5.1	21
274	Clinical outcome of pretreated B-cell chronic lymphocytic leukemia following alemtuzumab therapy: a retrospective study on various cytogenetic risk categories. <i>Annals of Oncology</i> , 2010, 21, 2410-2419.	0.6	21
275	Actinomycin D induces p53-independent cell death and prolongs survival in high-risk chronic lymphocytic leukemia. <i>Leukemia</i> , 2012, 26, 2508-2516.	3.3	21
276	Differential survival trends of stage II colorectal cancer patients relate to promoter methylation status of PCDH10, SPARC, and UCHL1. <i>Modern Pathology</i> , 2014, 27, 906-915.	2.9	21
277	Epidermal activation of Hedgehog signaling establishes an immunosuppressive microenvironment in basal cell carcinoma by modulating skin immunity. <i>Molecular Oncology</i> , 2020, 14, 1930-1946.	2.1	21
278	KEYNOTE-048: Progression after the next line of therapy following pembrolizumab (P) or P plus chemotherapy (P+C) vs EXTREME (E) as first-line (1L) therapy for recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC).. <i>Journal of Clinical Oncology</i> , 2020, 38, 6505-6505.	0.8	21
279	Intravascular large B-cell lymphoma with a fulminant clinical course: a case report with definite diagnosis post mortem. <i>Annals of Oncology</i> , 2002, 13, 1503-1506.	0.6	20
280	Fulvestrant (Faslodex™) in heavily pretreated postmenopausal patients with advanced breast cancer: single centre clinical experience from the compassionate use programme. <i>Breast Cancer Research and Treatment</i> , 2007, 106, 105-112.	1.1	20
281	APOBEC3 signature mutations in chronic lymphocytic leukemia. <i>Leukemia</i> , 2014, 28, 1929-1932.	3.3	20
282	Liver toxicity during temozolomide chemotherapy caused by Chinese herbs. <i>BMC Complementary and Alternative Medicine</i> , 2014, 14, 115.	3.7	20
283	The CXCR 4 and adhesion molecule expression of CD 34+ hematopoietic cells mobilized by conditioned medium addition of plerixafor to granulocyte colony-stimulating factor. <i>Transfusion</i> , 2014, 54, 2325-2335.	0.8	20
284	Poly-ligand profiling differentiates trastuzumab-treated breast cancer patients according to their outcomes. <i>Nature Communications</i> , 2018, 9, 1219.	5.8	20
285	Real-world non-interventional long-term post-authorization safety study of ruxolitinib in myelofibrosis. <i>British Journal of Haematology</i> , 2020, 191, 764-774.	1.2	20
286	Constitutive Expression of Fas (Apo-1/CD95) Ligand on Multiple Myeloma Cells: A Potential Mechanism of Tumor-Induced Suppression of Immune Surveillance. <i>Blood</i> , 1997, 90, 12-20.	0.6	20
287	Phase I study of AMG 160, a half-life extended bispecific T-cell engager (HLE BiTE) immune therapy targeting prostate-specific membrane antigen (PSMA), in patients with metastatic castration-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2020, 38, TPS261-TPS261.	0.8	20
288	Immunohistological assessment of bone marrow biopsies from patients with hairy cell leukemia: Changes following treatment with alpha-2-interferon and deoxycoformycin. <i>Leukemia Research</i> , 1989, 13, 377-383.	0.4	19

#	ARTICLE	IF	CITATIONS
289	Prognosis and Management Strategies of Lymphatic Neoplasias in the Elderly. <i>Oncology</i> , 1998, 55, 189-217.	0.9	19
290	Clinical Outcomes of 217 Patients with Acute Erythroleukemia According to Treatment Type and Line: A Retrospective Multinational Study. <i>International Journal of Molecular Sciences</i> , 2017, 18, 837.	1.8	19
291	Primary Gastrointestinal B-Cell Lymphoma - A Clinicopathological and Immunohistochemical Study of 61 Cases with an Evaluation of Prognostic Parameters. <i>Pathology Research and Practice</i> , 2001, 197, 385-393.	1.0	18
292	Reduced-intensity Chemotherapy in Patients With Advanced Stage Hodgkin Lymphoma. <i>HemaSphere</i> , 2017, 1, e5.	1.2	18
293	Microenvironment-induced CD44v6 promotes early disease progression in chronic lymphocytic leukemia. <i>Blood</i> , 2018, 131, 1337-1349.	0.6	18
294	Durable remissions with venetoclax monotherapy in secondary AML refractory to hypomethylating agents and high expression of BCL2 and/or BIM. <i>European Journal of Haematology</i> , 2019, 102, 437-441.	1.1	18
295	Pharmacokinetics of liposomal curcumin (Lipocurc,®) infusion: effect of co-medication in cancer patients and comparison with healthy individuals. <i>Cancer Chemotherapy and Pharmacology</i> , 2019, 83, 265-275.	1.1	18
296	Recent Interim Analysis of the HD11 Trial of the GHSG: Intensification of Chemotherapy and Reduction of Radiation Dose in Early Unfavorable Stage Hodgkin's Lymphoma. <i>Blood</i> , 2005, 106, 816-816.	0.6	18
297	CXCL12-induced VLA-4 activation is impaired in trisomy 12 chronic lymphocytic leukemia cells: a role for CCL21. <i>Oncotarget</i> , 2015, 6, 12048-12060.	0.8	18
298	A Randomized Phase II Study of Anti-CSF1 Monoclonal Antibody Lacnotuzumab (MCS110) Combined with Gemcitabine and Carboplatin in Advanced Triple-Negative Breast Cancer. <i>Clinical Cancer Research</i> , 2022, 28, 106-115.	3.2	18
299	Growth fraction of tumour cells and infiltration density with natural killer-like (HNK1+) cells in non-Hodgkin lymphomas. <i>British Journal of Haematology</i> , 1986, 62, 293-300.	1.2	17
300	Importance of an 85 kDa membrane glycoprotein for a variety of cell-cell interactions. <i>Molecular Immunology</i> , 1988, 25, 1053-1061.	1.0	17
301	Necrotizing Vasculitis Associated with Hepatitis C Virus Infection: Successful Treatment of Vasculitis with Interferon-Alpha despite Persistence of Mixed Cryoglobulinemia. <i>Dermatology</i> , 1995, 191, 43-45.	0.9	17
302	Interferon- α for the treatment of elderly patients with chronic myeloid leukaemia. <i>Leukemia Research</i> , 1998, 22, 881-886.	0.4	17
303	Alemtuzumab in chronic lymphocytic leukemia: final results of a large observational multicenter study in mostly pretreated patients. <i>Annals of Hematology</i> , 2014, 93, 267-277.	0.8	17
304	Immune checkpoint blockade in ovarian cancer. <i>Memo - Magazine of European Medical Oncology</i> , 2016, 9, 82-84.	0.3	17
305	B-cell-specific IRF4 deletion accelerates chronic lymphocytic leukemia development by enhanced tumor immune evasion. <i>Blood</i> , 2019, 134, 1717-1729.	0.6	17
306	Ixazomib+Thalidomide+Dexamethasone for induction therapy followed by Ixazomib maintenance treatment in patients with relapsed/refractory multiple myeloma. <i>British Journal of Cancer</i> , 2019, 121, 751-757.	2.9	17

#	ARTICLE	IF	CITATIONS
307	RNA editing contributes to epitranscriptome diversity in chronic lymphocytic leukemia. <i>Leukemia</i> , 2021, 35, 1053-1063.	3.3	17
308	Minimal Residual Disease (MRD) and T/NK Cell Dynamics during Fludarabine, Cyclophosphamide Plus Rituximab (FCR) Followed by Fludarabine Plus Rituximab (FR) and Remission Maintenance Therapy with Rituximab in Previously Untreated B-Chronic Lymphocytic Leukemia (B-CLL): Riskfactor Stratification in the Chairros Study. <i>Blood</i> , 2008, 112, 3175-3175.	0.6	17
309	Two years rituximab maintenance vs. observation after first line treatment with bendamustine plus rituximab (B-R) in patients with marginal zone lymphoma (MZL): Results of a prospective, randomized, multicenter phase 2 study (the StiL NHL7-2008 MAINTAIN trial).. <i>Journal of Clinical Oncology</i> , 2018, 36, 7515-7515.	0.8	17
310	Tuning the Rheostat of the Myelopoietic System via Fas and TRAIL. <i>Critical Reviews in Immunology</i> , 2003, 23, 301-322.	1.0	17
311	Pembrolizumab alone or with chemotherapy for recurrent or metastatic head and neck squamous cell carcinoma: Health-related quality-of-life results from KEYNOTE-048. <i>Oral Oncology</i> , 2022, 128, 105815.	0.8	17
312	In situ quantification of T-cell subsets, NK-like cells and macrophages in hodgkin's disease: Quantity and quality of infiltration density depends on histopathological subtypes. <i>Blut</i> , 1986, 53, 49-58.	1.2	16
313	LICC: L-BLP25 in patients with colorectal carcinoma after curative resection of hepatic metastases—a randomized, placebo-controlled, multicenter, multinational, double-blinded phase II trial. <i>BMC Cancer</i> , 2012, 12, 144.	1.1	16
314	Smart Home Precipitator for Biomass Furnaces: Design Considerations on a Small-Scale Electrostatic Precipitator. <i>IEEE Transactions on Industry Applications</i> , 2014, 50, 2219-2224.	3.3	16
315	The Role of CD44 in the Pathophysiology of Chronic Lymphocytic Leukemia. <i>Frontiers in Immunology</i> , 2015, 6, 177.	2.2	16
316	A Single Quantifiable Viral Load Is Predictive of Virological Failure in Human Immunodeficiency Virus (HIV)-Infected Patients on Combination Antiretroviral Therapy: The Austrian HIV Cohort Study. <i>Open Forum Infectious Diseases</i> , 2016, 3, ofw089.	0.4	16
317	Randomized Phase III Study of FOLFOX Alone and with Pegilodecakin as Second-line Therapy in Patients with Metastatic Pancreatic Cancer (SEQUOIA).. <i>Journal of Clinical Oncology</i> , 2020, 38, 637-637.	0.8	16
318	Everolimus in Postmenopausal, Hormone Receptor-Positive Advanced Breast Cancer: Summary and Results of an Austrian Expert Panel Discussion. <i>Breast Care</i> , 2013, 8, 293-299.	0.8	15
319	The clinical significance of fibrinogen plasma levels in patients with diffuse large B cell lymphoma. <i>Journal of Clinical Pathology</i> , 2016, 69, 326-330.	1.0	15
320	Impact of tumour RAS/BRAF status in a first-line study of panitumumab + FOLFIRI in patients with metastatic colorectal cancer. <i>British Journal of Cancer</i> , 2016, 115, 1215-1222.	2.9	15
321	CD4+ T cells, but not non-classical monocytes, are dispensable for the development of chronic lymphocytic leukemia in the TCL1-tg murine model. <i>Leukemia</i> , 2016, 30, 1409-1413.	3.3	15
322	Prognostic score in patients with recurrent or metastatic carcinoma of the head and neck treated with cetuximab and chemotherapy. <i>PLoS ONE</i> , 2017, 12, e0180995.	1.1	15
323	Therapy Line and Associated Predictors of Response to PD-1/PD-L1-Inhibitor Monotherapy in Advanced Non-small-Cell Lung Cancer: A Retrospective Bi-centric Cohort Study. <i>Targeted Oncology</i> , 2019, 14, 707-717.	1.7	15
324	Association between antibiotics use and outcome in patients with NSCLC treated with immunotherapeutics. <i>Annals of Oncology</i> , 2019, 30, 652-653.	0.6	15

#	ARTICLE	IF	CITATIONS
325	Cytotoxic Properties of Damiana (<i>Turnera diffusa</i>) Extracts and Constituents and A Validated Quantitative UHPLC-DAD Assay. <i>Molecules</i> , 2019, 24, 855.	1.7	15
326	Lenalidomide maintenance for diffuse large B-cell lymphoma patients responding to R-CHOP: quality of life, dosing, and safety results from the randomised controlled REMARC study. <i>British Journal of Haematology</i> , 2020, 189, 84-96.	1.2	15
327	SAMHD1 restrains aberrant nucleotide insertions at repair junctions generated by DNA end joining. <i>Nucleic Acids Research</i> , 2021, 49, 2598-2608.	6.5	15
328	Accelerating clinical trial implementation in the context of the COVID-19 pandemic: challenges, lessons learned and recommendations from DisCoVeRy and the EU-SolidAct EU response group. <i>Clinical Microbiology and Infection</i> , 2022, 28, 1-5.	2.8	15
329	Safety and efficacy of durvalumab with R-CHOP or R2-CHOP in untreated, high-risk DLBCL: a phase 2, open-label trial. <i>International Journal of Hematology</i> , 2022, 115, 222-232.	0.7	15
330	Long-term outcomes of adjuvant denosumab in breast cancer: Fracture reduction and survival results from 3,425 patients in the randomised, double-blind, placebo-controlled ABCSG-18 trial.. <i>Journal of Clinical Oncology</i> , 2022, 40, 507-507.	0.8	15
331	Improved Efficacy of Tafasitamab plus Lenalidomide versus Systemic Therapies for Relapsed/Refractory DLBCL: RE-MIND2, an Observational Retrospective Matched Cohort Study. <i>Clinical Cancer Research</i> , 2022, 28, 4003-4017.	3.2	15
332	Interleukin-15 as a potential costimulatory cytokine in CD154 gene therapy of chronic lymphocytic leukemia. <i>Blood</i> , 2002, 99, 722-723.	0.6	14
333	Initial evaluation of the Roche COBAS TaqMan HIV-1 v2.0 assay for determining viral load in HIV-infected individuals. <i>Antiviral Therapy</i> , 2009, 14, 1189-1193.	0.6	14
334	The clinical potential of temsirolimus in second or later lines of treatment for metastatic renal cell carcinoma. <i>Expert Review of Anticancer Therapy</i> , 2013, 13, 1021-1033.	1.1	14
335	ASCO 2018 highlights: metastatic breast cancer. <i>Memo - Magazine of European Medical Oncology</i> , 2018, 11, 276-279.	0.3	14
336	Sidedness and TP53 mutations impact OS in anti-EGFR but not anti-VEGF treated mCRC - an analysis of the KRAS registry of the AGMT (Arbeitsgemeinschaft Medikament- und Tumortherapie). <i>BMC Cancer</i> , 2018, 18, 11.	1.1	14
337	Regorafenib Is Associated With Increased Skeletal Muscle Loss Compared to TAS-102 in Metastatic Colorectal Cancer. <i>Clinical Colorectal Cancer</i> , 2019, 18, 159-166.e3.	1.0	14
338	Quality of life in patients with relapsed/refractory multiple myeloma during ixazomib-thalidomide-dexamethasone induction and ixazomib maintenance therapy and comparison to the general population. <i>Leukemia and Lymphoma</i> , 2020, 61, 377-386.	0.6	14
339	Efficacy and safety of tailored and dose-dense adjuvant chemotherapy and trastuzumab for resected HER2-positive breast cancer: Results from the phase 3 PANTHER trial. <i>Cancer</i> , 2020, 126, 1175-1182.	2.0	14
340	Abstract S2-06: Survival advantage of anastrozol compared to tamoxifen for lobular breast cancer in the ABCSG-8 study. , 2015, , .		14
341	Distribution and Metabolism of Lipocurcâ„¢ (Liposomal Curcumin) in Dog and Human Blood Cells: Species Selectivity and Pharmacokinetic Relevance. <i>Anticancer Research</i> , 2017, 37, 3483-3492.	0.5	14
342	Apoptosis and Therapy of Malignant Diseases of the Hematopoietic System. <i>International Archives of Allergy and Immunology</i> , 1994, 105, 368-373.	0.9	13

#	ARTICLE	IF	CITATIONS
343	Functional granulocyte/macrophage colony stimulating factor receptor is constitutively expressed on neoplastic plasma cells and mediates tumour cell longevity. <i>British Journal of Haematology</i> , 1998, 102, 1069-1080.	1.2	13
344	Adjuvant Sequencing of Tamoxifen and Anastrozole Is Superior to Tamoxifen Alone in Postmenopausal Women with Low Proliferating Breast Cancer. <i>Clinical Cancer Research</i> , 2011, 17, 7828-7834.	3.2	13
345	Bone-Targeted Therapy in Metastatic Breast Cancer - All Well-Established Knowledge?. <i>Breast Care</i> , 2014, 9, 323-330.	0.8	13
346	Performance Characteristics of the Cobas Ampliprep/Cobas Taqman V2.0 and the Abbott Realtime Hepatitis C Assays - Implications for Response-Guided Therapy in Genotype 1 Infections. <i>Antiviral Therapy</i> , 2014, 19, 449-454.	0.6	13
347	Adipocyte-derived players in hematologic tumors: useful novel targets?. <i>Expert Opinion on Biological Therapy</i> , 2015, 15, 61-77.	1.4	13
348	ILK Induction in Lymphoid Organs by a TNF- α -Regulated Pathway Promotes the Development of Chronic Lymphocytic Leukemia. <i>Cancer Research</i> , 2016, 76, 2186-2196.	0.4	13
349	Alemtuzumab added to CHOP for treatment of peripheral T-cell lymphoma (pTNHL) of the elderly: Final results of 116 patients treated in the international ACT-2 phase III trial.. <i>Journal of Clinical Oncology</i> , 2016, 34, 7500-7500.	0.8	13
350	Cytokine Priming of the Granulocyte Respiratory Burst in Myelodysplastic Syndromes. <i>Leukemia and Lymphoma</i> , 1997, 27, 137-143.	0.6	12
351	SNP309 as predictor for sensitivity of CLL cells to the MDM2 inhibitor nutlin-3a. <i>Blood</i> , 2008, 112, 2168-2168.	0.6	12
352	Vincristine, Idarubicin, Dexamethasone and Thalidomide in Scleromyxoedema. <i>Acta Dermato-Venereologica</i> , 2009, 89, 631-635.	0.6	12
353	Effect of KRAS codon13 mutations in patients with advanced colorectal cancer (advanced CRC) under oxaliplatin containing chemotherapy. Results from a translational study of the AIO colorectal study group. <i>BMC Cancer</i> , 2012, 12, 349.	1.1	12
354	Systemic effect of catumaxomab in a patient with metastasized colorectal cancer: a case report. <i>BMC Cancer</i> , 2013, 13, 618.	1.1	12
355	CYP39A1 polymorphism is associated with toxicity during intensive induction chemotherapy in patients with advanced head and neck cancer. <i>BMC Cancer</i> , 2015, 15, 725.	1.1	12
356	A phase 1 dose escalation study of BI 831266, an inhibitor of Aurora kinase B, in patients with advanced solid tumors. <i>Investigational New Drugs</i> , 2015, 33, 409-422.	1.2	12
357	Transient congenital dilated cardiomyopathy after maternal R-CHOP chemotherapy during pregnancy. <i>Reproductive Toxicology</i> , 2017, 71, 146-149.	1.3	12
358	Novel models for prediction of benefit and toxicity with FOLFIRINOX treatment of pancreatic cancer using clinically available parameters. <i>PLoS ONE</i> , 2018, 13, e0206688.	1.1	12
359	Ixazomib in combination with carboplatin in pretreated women with advanced triple-negative breast cancer, a phase I/II trial of the AGMT (AGMT MBC-10 trial). <i>BMC Cancer</i> , 2018, 18, 1074.	1.1	12
360	Treatment with brentuximab vedotin plus bendamustine in unselected patients with CD30-positive aggressive lymphomas. <i>European Journal of Haematology</i> , 2020, 104, 251-258.	1.1	12

#	ARTICLE	IF	CITATIONS
361	Efficacy and safety of everolimus plus exemestane in patients with HR+, HER2 ⁺ advanced breast cancer progressing on/after prior endocrine therapy in routine clinical practice: Primary results from the non-interventional study, STEPAUT. <i>Breast</i> , 2020, 50, 64-70.	0.9	12
362	Intensified treatment of patients with early stage, unfavourable Hodgkin lymphoma: long-term follow-up of a randomised, international phase 3 trial of the German Hodgkin Study Group (GHSG) Tj ETQq0 0 0 rg212/Overlook 10 Tf 50	0.9	10
363	Long-Term Efficacy and Safety of Ropoginterferon Alfa-2b in Patients with Polycythemia Vera ^{â€} Final Phase I/II Pegivera Study Results. <i>Blood</i> , 2018, 132, 3030-3030.	0.6	12
364	Addition of Rituximab to BEACOPPescalated to Improve the Outcome of Early Interim PET Positive Advanced Stage Hodgkin Lymphoma Patients: Second Planned Interim Analysis of the HD18 Study.. <i>Blood</i> , 2014, 124, 500-500.	0.6	12
365	Cobas Ampliprep/Cobas TaqMan HIV-1 v2.0 Assay: Consequences at the Cohort Level. <i>PLoS ONE</i> , 2013, 8, e74024.	1.1	12
366	Expression Levels of CD38 in Tumor Cells and T-Cells Are of Prognostic Value in B-CLL.. <i>Blood</i> , 2005, 106, 1189-1189.	0.6	12
367	A New Sesquiterpene Lactone Sulfate from <i>Reichardia gaditana</i> (Asteraceae). <i>Zeitschrift Fur Naturforschung - Section B Journal of Chemical Sciences</i> , 2007, 62, 132-134.	0.3	11
368	Renal safety profiles of ibandronate 6 mg infused over 15 and 60 min: a randomized, open-label study. <i>Annals of Oncology</i> , 2008, 19, 1266-1270.	0.6	11
369	Maintaining Bone Density in Patients Undergoing Treatment for Breast Cancer: Is There an Adjuvant Benefit?. <i>Clinical Breast Cancer</i> , 2009, 9, S18-S27.	1.1	11
370	Multicenter Phase II Study of Pegylated Liposomal Doxorubicin in Combination with Vinorelbine as First-Line Treatment in Elderly Patients with Metastatic Breast Cancer. <i>Oncology Research and Treatment</i> , 2009, 32, 18-24.	0.8	11
371	Imprecision and DNA Break Repair Biased towards Incompatible End Joining in Leukemia. <i>Molecular Cancer Research</i> , 2018, 16, 428-438.	1.5	11
372	Adjuvant MUC vaccination with tecemotide after resection of colorectal liver metastases: a randomized, double-blind, placebo-controlled, multicenter AIO phase II trial (LICC). <i>Oncolmmunology</i> , 2020, 9, 1806680.	2.1	11
373	<p>Treatment Landscape for Patients with HER2-Positive Metastatic Breast Cancer: A Review on Emerging Treatment Options</p>. <i>Cancer Management and Research</i> , 2020, Volume 12, 10615-10629.	0.9	11
374	RNA Editing Alters miRNA Function in Chronic Lymphocytic Leukemia. <i>Cancers</i> , 2020, 12, 1159.	1.7	11
375	Lapatinib-plus-pegylated liposomal doxorubicin in advanced HER2-positive breast cancer following trastuzumab: a phase II trial. <i>Anticancer Research</i> , 2015, 35, 517-21.	0.5	11
376	Is higher income and educational status associated with poorer outcome in patients with Hodgkin's disease?. <i>European Journal of Haematology</i> , 2004, 73, 318-324.	1.1	10
377	Massive infiltration of bone marrow in colon carcinoma after treatment with activated protein C. <i>Wiener Klinische Wochenschrift</i> , 2007, 119, 254-258.	1.0	10
378	Chemokine-dependent B cell ^{â€} T cell interactions in chronic lymphocytic leukemia and multiple myeloma ^{â€} targets for therapeutic intervention?. <i>Expert Opinion on Biological Therapy</i> , 2012, 12, 425-441.	1.4	10

#	ARTICLE	IF	CITATIONS
379	B cell receptor usage correlates with the sensitivity to CD40 stimulation and the occurrence of CD4+ T cell clonality in chronic lymphocytic leukemia. <i>Haematologica</i> , 2015, 100, e307-10.	1.7	10
380	Endothelin-1 genetic polymorphism as predictive marker for bevacizumab in metastatic breast cancer. <i>Pharmacogenomics Journal</i> , 2017, 17, 344-350.	0.9	10
381	Intense Uptake of Liposomal Curcumin by Multiple Myeloma Cell Lines: Comparison to Normal Lymphocytes, Red Blood Cells and Chronic Lymphocytic Leukemia Cells. <i>Anticancer Research</i> , 2019, 39, 1161-1168.	0.5	10
382	Neutropenic complications in the PANTHER phase III study of adjuvant tailored dose-dense chemotherapy in early breast cancer. <i>Acta Oncologica</i> , 2020, 59, 75-81.	0.8	10
383	Impact of PD-L1 Scores and Changes on Clinical Outcome in Rectal Cancer Patients Undergoing Neoadjuvant Chemoradiotherapy. <i>Journal of Clinical Medicine</i> , 2020, 9, 2775.	1.0	10
384	Pretreatment with ibrutinib reduces cytokine secretion and limits the risk of obinutuzumab-induced infusion-related reactions in patients with CLL: analysis from the iLLUMINATE study. <i>Annals of Hematology</i> , 2021, 100, 1733-1742.	0.8	10
385	Neoadjuvant Chemotherapy with Capecitabine, Oxaliplatin and Bevacizumab Followed by Concomitant Chemoradiation and Surgical Resection in Locally Advanced Rectal Cancer with High Risk of Recurrence – A Phase II Study. <i>Anticancer Research</i> , 2017, 37, 2683-2691.	0.5	10
386	Abscopal Effect of Radiotherapy and Nivolumab in Relapsed or Refractory Hodgkin Lymphoma (AERN): An International Multicenter Single-Arm Two-Stage Phase II GHSG Trial. <i>Blood</i> , 2019, 134, 1547-1547.	0.6	10
387	abl oncogene expression in non-Hodgkin lymphomas: Correlation to histological differentiation and clinical status. <i>International Journal of Cancer</i> , 1988, 42, 529-538.	2.3	9
388	Diagnostic algorithms, monitoring, prognostication, and therapy in chronic myeloid leukemia (CML): a proposal of the Austrian CML platform. <i>Wiener Klinische Wochenschrift</i> , 2008, 120, 697-709.	1.0	9
389	The Austrian fulvestrant registry: results from a prospective observation of fulvestrant in postmenopausal patients with metastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , 2009, 115, 373-380.	1.1	9
390	Zoledronic acid for adjuvant use in patients with breast cancer. <i>Expert Review of Anticancer Therapy</i> , 2011, 11, 333-349.	1.1	9
391	An international, multicenter, prospective, observational study of neutropenia in patients being treated with lenalidomide+dexamethasone for relapsed or relapsed/refractory multiple myeloma (RR-MM). <i>American Journal of Hematology</i> , 2016, 91, 806-811.	2.0	9
392	Extensive Leptomeningeal Intracranial and Spinal Metastases in a Patient with a Supratentorial Glioblastoma Multiforme, IDH-Wildtype. <i>World Neurosurgery</i> , 2018, 120, 442-447.	0.7	9
393	C-Reactive Protein and Neutrophil/Lymphocytes Ratio: Prognostic Indicator for Doubling overall survival Prediction in Pancreatic Cancer Patients. <i>Journal of Clinical Medicine</i> , 2019, 8, 1791.	1.0	9
394	miRNA-Based Therapeutics in the Era of Immune-Checkpoint Inhibitors. <i>Pharmaceuticals</i> , 2021, 14, 89.	1.7	9
395	Eight Cycles of BEACOPP Escalated Compared with 4 Cycles of BEACOPP Escalated Followed by 4 Cycles of BEACOPP Baseline with or without Radiotherapy in Patients in Advanced Stage Hodgkin Lymphoma (HL): Final Analysis of the Randomised HD12 Trial of the German Hodgkin Study Group (GHSG). <i>Blood</i> , 2008, 112, 1558-1558.	0.6	9
396	Dose-Intensified Combined Modality Treatment with 2 Cycles of BEACOPP Escalated Followed by 2 Cycles of ABVD and Involved Field Radiotherapy (IF-RT) Is Superior to 4 Cycles of ABVD and IFRT in Patients with Early Unfavourable Hodgkin Lymphoma (HL): An Analysis of the German Hodgkin Study Group (GHSG) HD14 Trial. <i>Blood</i> , 2008, 112, 367-367.	0.6	9

#	ARTICLE	IF	CITATIONS
397	Oxaliplatin/Irinotecan/Bevacizumab Followed by Docetaxel/ Bevacizumab in Inoperable Locally Advanced or Metastatic Gastric Cancer Patients â€“ AGMT_GASTRIC-3. , 2017, 37, 5553-5558.		9
398	Recent Advances in Pancreatic Cancer: Novel Prognostic Biomarkers and Targeted Therapyâ€™A Review of the Literature. <i>Biomolecules</i> , 2021, 11, 1469.	1.8	9
399	Abstract GS1-00: Single-cell spatial analysis by imaging mass cytometry and immunotherapy response in triple-negative breast cancer (TNBC) in the NeoTRIPaPDL1 trial. <i>Cancer Research</i> , 2022, 82, GS1-00-GS1-00.	0.4	9
400	1,10-Epoxyhypocretenolides from the Azorean Endemic <i>Leontodon rigens</i> (Asteraceae). <i>Letters in Organic Chemistry</i> , 2005, 2, 461-464.	0.2	8
401	Combination Therapy of Lapatinib and Capecitabine for ErbB2-Positive Metastatic or Locally Advanced Breast Cancer: Results from the Lapatinib Expanded Access Program (LEAP) in Central and Eastern Europe. <i>Onkologie</i> , 2011, 34, 233-238.	1.1	8
402	Successful alemtuzumab retreatment in progressive B-cell chronic lymphocytic leukemia: a multicenter survey in 30 patients. <i>Annals of Hematology</i> , 2011, 90, 1083-1091.	0.8	8
403	Nilotinib as frontline and second-line therapy in chronic myeloid leukemia: Open questions. <i>Critical Reviews in Oncology/Hematology</i> , 2012, 82, 370-377.	2.0	8
404	Anti-Hu Antibody Associated Paraneoplastic Cerebellar Degeneration in Head and Neck Cancer. <i>BMC Cancer</i> , 2015, 15, 996.	1.1	8
405	The AKT 1 isoform plays a dominant role in the survival and chemoresistance of chronic lymphocytic leukaemia cells. <i>British Journal of Haematology</i> , 2016, 172, 815-819.	1.2	8
406	CDK4/6 inhibition in luminal breast cancer. <i>Memo - Magazine of European Medical Oncology</i> , 2016, 9, 76-81.	0.3	8
407	SABCS 2016: systemic therapy for metastatic breast cancer. <i>Memo - Magazine of European Medical Oncology</i> , 2017, 10, 86-89.	0.3	8
408	Antiangiogenic therapy in breast cancer. <i>Memo - Magazine of European Medical Oncology</i> , 2017, 10, 194-201.	0.3	8
409	A phase 1 study to evaluate the feasibility and efficacy of the addition of ropeginterferon alphaâ€™2b to imatinib treatment in patients with chronic phase chronic myeloid leukemia (CML) not achieving a deep molecular response (molecular remission 4.5)â€™AGMT_CML 1. <i>Hematological Oncology</i> , 2020, 38, 792-798.	0.8	8
410	Incidence of central nervous system relapses in patients with DLBCL treated with lenalidomide as maintenance after R-CHOP. <i>Blood Advances</i> , 2021, 5, 2965-2968.	2.5	8
411	Pegfilgrastim Supports Delivery of CHOP-R Chemotherapy Administered Every 14 Days: A Randomised Phase II Study.. <i>Blood</i> , 2004, 104, 3311-3311.	0.6	8
412	HD12 Randomised Trial Comparing 8 Dose-Escalated Cycles of BEACOPP with 4 Escalated and 4 Baseline Cycles in Patients with Advanced Stage Hodgkin Lymphoma (HL): An Analysis of the German Hodgkin Lymphoma Study Group (GHSG), University of Cologne, D-50924 Cologne, Germany.. <i>Blood</i> , 2006, 108, 99-99.	0.6	8
413	Rituximab Maintenance after Chemoimmunotherapy Induction in 1st and 2nd Line Improves Progression Free Survival: Planned Interim Analysis of the International Randomized AGMT-CLL8/a Maintenance Trial. <i>Blood</i> , 2014, 124, 20-20.	0.6	8
414	CD1d expression on chronic lymphocytic leukemia B cells affects disease progression and induces T cell skewing in CD8 positive and CD4CD8 double negative T cells. <i>Oncotarget</i> , 2016, 7, 49459-49469.	0.8	8

#	ARTICLE	IF	CITATIONS
415	Evaluation of circulating cell-free DNA as a molecular monitoring tool in patients with metastatic cancer. <i>Oncology Letters</i> , 2020, 19, 1551-1558.	0.8	8
416	Tafasitamab Plus Lenalidomide Versus Pola-BR, R2, and CAR T: Comparing Outcomes from RE-MIND2, an Observational, Retrospective Cohort Study in Relapsed/Refractory Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2021, 138, 183-183.	0.6	8
417	Multimodal Therapy in Life-Threatening Cerebral Lupus erythematosus: The Benefit of Cerebrospinal Fluid Pheresis. <i>International Archives of Allergy and Immunology</i> , 1995, 107, 592-594.	0.9	7
418	Continuous prednisolone versus conventional prednisolone with VMCP-interferon-alpha2b as first-line chemotherapy in elderly patients with multiple myeloma. <i>British Journal of Haematology</i> , 2005, 131, 329-337.	1.2	7
419	Differential diagnostic challenge of chronic neutrophilic leukemia in a patient with prolonged leukocytosis. <i>Journal of Hematopathology</i> , 2008, 1, 23-27.	0.2	7
420	Infusion reactions to the chimeric EGFR inhibitor cetuximab—change to the fully human anti-EGFR monoclonal antibody panitumumab is safe. <i>Annals of Oncology</i> , 2011, 22, 486-487.	0.6	7
421	Influence of the American ODAC Statement on Austrian Bevacizumab Prescribing Practice for Metastatic Breast Cancer. <i>Oncologist</i> , 2012, 17, e13-e17.	1.9	7
422	Assessment of TP53 functionality in chronic lymphocytic leukaemia by different assays; an ERIC-wide approach. <i>British Journal of Haematology</i> , 2014, 167, 565-569.	1.2	7
423	Kasabach-Merritt phenomenon in hepatic angiosarcoma. <i>British Journal of Haematology</i> , 2014, 167, 716-718.	1.2	7
424	Alternative splice variants of AID are not stoichiometrically present at the protein level in chronic lymphocytic leukemia. <i>European Journal of Immunology</i> , 2014, 44, 2175-2187.	1.6	7
425	A prospective, multicenter pilot study to investigate the feasibility and safety of a 1-year controlled exercise training after adjuvant chemotherapy in colorectal cancer patients. <i>Supportive Care in Cancer</i> , 2018, 26, 1345-1352.	1.0	7
426	Outcome of Patients With Early-Stage Infradiaphragmatic Hodgkin Lymphoma: A Comprehensive Analysis From the German Hodgkin Study Group. <i>Journal of Clinical Oncology</i> , 2018, 36, 2603-2611.	0.8	7
427	Rituximab maintenance overcomes the negative prognostic factor of obesity in CLL: Subgroup analysis of the international randomized AGMT CLL maintenance trial. <i>Cancer Medicine</i> , 2019, 8, 1401-1405.	1.3	7
428	Low Expression of miR-20a-5p Predicts Benefit to Bevacizumab in Metastatic Breast Cancer Patients Treated within the TANIA Phase III Trial. <i>Journal of Clinical Medicine</i> , 2020, 9, 1663.	1.0	7
429	Patterns of Thromboembolism in Patients with Advanced Pancreatic Cancer Undergoing First-Line Chemotherapy with FOLFIRINOX or Gemcitabine/nab-Paclitaxel. <i>Thrombosis and Haemostasis</i> , 2022, 122, 633-645.	1.8	7
430	A Combination of Fludarabine/Rituximab with Escalating Doses of Lenalidomide in Previously Untreated Chronic Lymphocytic Leukemia (CLL): The REVLIRIT CLL5 AGMT Phase I/II Study, Clinical and Exploratory Analyses of Induction Results. <i>Blood</i> , 2011, 118, 292-292.	0.6	7
431	Sex-Based Clinical Outcome in Advanced NSCLC Patients Undergoing PD-1/PD-L1 Inhibitor Therapy—A Retrospective Bi-Centric Cohort Study. <i>Cancers</i> , 2022, 14, 93.	1.7	7
432	Gastric cancer cell lines lack Fas ligand (FasL) expression but kill T cells via a FasL independent pathway Reply. <i>Gut</i> , 2000, 46, 738-740.	6.1	6

#	ARTICLE	IF	CITATIONS
433	Diffuse Large B-cell Lymphoma with Infiltration-Associated Peripheral Neuropathy and Paraneoplastic Myopathy with a Prolonged Course Over Seven Years. <i>Leukemia and Lymphoma</i> , 2002, 43, 1687-1690.	0.6	6
434	Long-term results of dose density therapy in patients with aggressive lymphoma. <i>Annals of Hematology</i> , 2005, 84, 217-222.	0.8	6
435	Dose-dense therapy improves survival in aggressive non-Hodgkin's lymphoma. <i>Annals of Hematology</i> , 2010, 89, 273-282.	0.8	6
436	Sentinel Node Biopsy After Primary Chemotherapy in Breast Cancer: A Note of Caution from Results of ABCSG-14. <i>Breast Journal</i> , 2011, 17, 230-238.	0.4	6
437	Influence of body mass index on survival in indolent and mantle cell lymphomas: analysis of the StiL NHL1 trial. <i>Annals of Hematology</i> , 2017, 96, 1155-1162.	0.8	6
438	Fludarabine and rituximab with escalating doses of lenalidomide followed by lenalidomide/rituximab maintenance in previously untreated chronic lymphocytic leukaemia (CLL): the REVLIRIT CLL-5 AGMT phase I/II study. <i>Annals of Hematology</i> , 2018, 97, 1825-1839.	0.8	6
439	Lignans and sesquiterpene lactones from <i>Hypochaeris radicata</i> subsp. <i>neapolitana</i> (Asteraceae.) Tj ETQq1 1 0.784314 rgBT /Overlock 10 1.4 6		
440	Long-term (up to 16 months) health-related quality of life after adjuvant tailored dose-dense chemotherapy vs. standard three-weekly chemotherapy in women with high-risk early breast cancer. <i>Breast Cancer Research and Treatment</i> , 2020, 181, 87-96.	1.1	6
441	Local and Central Evaluation of HER2 Positivity and Clinical Outcome in Advanced Gastric and Gastroesophageal Cancer: Results from the AGMT GASTRIC-5 Registry. <i>Journal of Clinical Medicine</i> , 2020, 9, 935.	1.0	6
442	Vinorelbine as substitute for vincristine in patients with diffuse large B cell lymphoma and vincristine-induced neuropathy. <i>Supportive Care in Cancer</i> , 2021, 29, 5197-5207.	1.0	6
443	Re-Sensitizing Tumor Cells to Cancer Drugs with Epigenetic Regulators. <i>Current Cancer Drug Targets</i> , 2021, 21, 353-359.	0.8	6
444	Evaluation of circulating cell-free KRAS mutational status as a molecular monitoring tool in patients with pancreatic cancer. <i>Pancreatology</i> , 2021, 21, 1466-1471.	0.5	6
445	Retreatment with Alemtuzumab after a First, Successful Alemtuzumab Treatment in B-CLL. <i>Blood</i> , 2007, 110, 4714-4714.	0.6	6
446	Non-Pegylated Liposomal Encapsulated Doxorubicin Reduces Cardiotoxicity in 1st Line Treatment of Diffuse Large B-Cell Lymphoma (DLBCL). Final Results of a Randomized Trial. <i>Blood</i> , 2011, 118, 2676-2676.	0.6	6
447	Efficacy and Safety Of AOP2014/P1101, a Novel, Investigational Mono-Pegylated Proline-Interferon Alpha-2b, In Patients With Polycythemia Vera (PV): Update On 51 Patients From The Ongoing Phase I/II Pegivera Study. <i>Blood</i> , 2013, 122, 4046-4046.	0.6	6
448	Adjuvant denosumab in breast cancer: Results from 3,425 postmenopausal patients of the ABCSG-18 trial. <i>Journal of Clinical Oncology</i> , 2015, 33, 504-504.	0.8	6
449	CCR10/CCL27 crosstalk contributes to failure of proteasome-inhibitors in multiple myeloma. <i>Oncotarget</i> , 2016, 7, 78605-78618.	0.8	6
450	Sequential immunotherapy in a patient with primary refractory Hodgkin lymphoma and novel mutations. <i>Oncotarget</i> , 2018, 9, 20928-20940.	0.8	6

#	ARTICLE	IF	CITATIONS
451	Distribution of Curcumin and THC in Peripheral Blood Mononuclear Cells Isolated from Healthy Individuals and Patients with Chronic Lymphocytic Leukemia. <i>Anticancer Research</i> , 2018, 38, 121-130.	0.5	6
452	Prognosis and Management Strategies of Lymphatic Neoplasias in the Elderly. <i>Oncology</i> , 1998, 55, 265-275.	0.9	5
453	The Still Long and Winding Road to Neoadjuvant Systemic Therapy as the Standard of Care in Breast Cancer. <i>Breast Care</i> , 2006, 1, 352-357.	0.8	5
454	Bisphosphonates as adjuvant therapy for breast cancer. <i>Current Breast Cancer Reports</i> , 2009, 1, 54-63.	0.5	5
455	Hodgkin lymphoma in Tyrol—a population-based study. <i>Annals of Hematology</i> , 2009, 88, 449-456.	0.8	5
456	A phase I study of lenalidomide in patients with chronic myelomonocytic leukemia (CMML) in the AGMT_CMML-1. <i>Leukemia and Lymphoma</i> , 2018, 59, 1121-1126.	0.6	5
457	SABCS 2017: lifestyle factors, hormone receptor-positive advanced disease, liquid biopsies, and prognosis. <i>Memo - Magazine of European Medical Oncology</i> , 2018, 11, 208-212.	0.3	5
458	Prevalence of comorbidity in cancer patients scheduled for systemic anticancer treatment in Austria. <i>Memo - Magazine of European Medical Oncology</i> , 2019, 12, 290-296.	0.3	5
459	Patterns of care in metastatic pancreatic cancer: patient selection in clinical routine. <i>Therapeutic Advances in Gastroenterology</i> , 2019, 12, 175628481987763.	1.4	5
460	A cross-trial comparison of single-agent ibrutinib versus chlorambucil-obinutuzumab in previously untreated patients with chronic lymphocytic leukemia or small lymphocytic lymphoma. <i>Haematologica</i> , 2020, 105, e164-e168.	1.7	5
461	Ensuring center quality, proper patient selection and fair access to chimeric antigen receptor T-cell therapy: position statement of the Austrian CAR-T Cell Network. <i>Memo - Magazine of European Medical Oncology</i> , 2020, 13, 27-31.	0.3	5
462	AID Contributes to Accelerated Disease Progression in the TCL1 Mouse Transplant Model for CLL. <i>Cancers</i> , 2021, 13, 2619.	1.7	5
463	Pharmacokinetics and safety of capmatinib with food in patients with MET-dysregulated advanced solid tumors. <i>Clinical Therapeutics</i> , 2021, 43, 1092-1111.	1.1	5
464	Docetaxel, cisplatin and 5-FU compared with docetaxel, cisplatin and cetuximab as induction chemotherapy in advanced squamous cell carcinoma of the head and neck: Results of a randomised phase II AGMT trial. <i>European Journal of Cancer</i> , 2021, 151, 201-210.	1.3	5
465	First Interim Efficacy and Safety Analysis of an International Phase III Randomized Trial in Newly Diagnosed Systemic Peripheral T-Cell Lymphoma Treated with Chemotherapy with or without Alectuzumab and Consolidated by High Dose Therapy. <i>Blood</i> , 2012, 120, 57-57.	0.6	5
466	Azacitidine in Acute Myeloid Leukemia with >30% Bone Marrow Blasts and <15 G/L White Blood Cell Count: Results from the Austrian Azacitidine Registry of the AGMT Study Group Versus Randomized Controlled Phase III Clinical Trial Data. <i>Blood</i> , 2015, 126, 2515-2515.	0.6	5
467	Predicting local recurrence using PAM50 in postmenopausal endocrine responsive breast cancer patients. <i>Journal of Clinical Oncology</i> , 2014, 32, 1008-1008.	0.8	5
468	Trial in progress: A phase I study of AMG 199, a half-life extended bispecific T-cell engager (HLE BiTE) immune therapy, targeting MUC17 in patients with gastric and gastroesophageal junction (G/GE) cancer. <i>Journal of Clinical Oncology</i> , 2020, 38, TPS4649-TPS4649.	0.8	5

#	ARTICLE	IF	CITATIONS
469	Assessment of Pharmacokinetic Interaction Between Capecitabine and Cetuximab in Metastatic Colorectal Cancer Patients. <i>Anticancer Research</i> , 2016, 36, 4715-4724.	0.5	5
470	The POLARIX Study: Polatuzumab Vedotin with Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (pola-R-CHP) Versus Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone (R-CHOP) Therapy in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2021, 138, LBA-1-LBA-1.	0.6	5
471	Diffuse large B-cell lymphoma as a second, clonally unrelated lymphoproliferative disease in a patient with IgM monoclonal gammopathy of undetermined significance (MGUS) and concomitant polycythemia vera rubra. <i>Leukemia and Lymphoma</i> , 2006, 47, 940-943.	0.6	4
472	An uncommon cause of anaemia: Sheehan's syndrome. <i>Wiener Klinische Wochenschrift</i> , 2010, 122, 717-719.	1.0	4
473	Efficacy of Temozolomide after Previous Treatment with Sunitinib, Sorafenib or Everolimus in Advanced Renal Cell Cancer. <i>Oncology</i> , 2011, 80, 34-41.	0.9	4
474	Novel treatment avenues for peripheral T-cell lymphomas. <i>Expert Opinion on Drug Discovery</i> , 2012, 7, 1149-1163.	2.5	4
475	A case of long-term remission with ofatumumab maintenance therapy in multiply relapsed and rituximab-refractory chronic lymphocytic leukaemia with deletion 17p. <i>European Journal of Haematology</i> , 2013, 90, 349-350.	1.1	4
476	VLA-4 and CXCR4 overexpression in bone marrow of an aleukemic B-cell acute lymphoblastic leukemia presenting with osteolytic bone lesions. <i>Leukemia and Lymphoma</i> , 2015, 56, 2465-2467.	0.6	4
477	Fluorouracil and Dihydropyrimidine Dehydrogenase Genotyping. <i>Journal of Clinical Oncology</i> , 2016, 34, 2433-2434.	0.8	4
478	Low Beclin-1 expression predicts improved overall survival in patients treated with immunomodulatory drugs for multiple myeloma and identifies autophagy inhibition as a promising potentially druggable new therapeutic target: an analysis from The Austrian Myeloma Registry (AMR). <i>Leukemia and Lymphoma</i> , 2016, 57, 2330-2341.	0.6	4
479	Nonmetastatic pancreatic cancer. <i>Strahlentherapie Und Onkologie</i> , 2018, 194, 627-637.	1.0	4
480	Investigating epigenetic effects of activation-induced deaminase in chronic lymphocytic leukemia. <i>PLoS ONE</i> , 2018, 13, e0208753.	1.1	4
481	Treatment Algorithm for Patients With Gastric Adenocarcinoma: An Austrian Consensus on Systemic Therapy. <i>Anticancer Research</i> , 2019, 39, 4589-4596.	0.5	4
482	IDO in MDS/AML disease progression and its role in resistance to azacitidine: a potential new drug target?. <i>British Journal of Haematology</i> , 2020, 190, 314-317.	1.2	4
483	Comparison of high tone therapy and transcutaneous electrical nerve stimulation therapy in chemotherapy-induced polyneuropathy. <i>Medicine (United States)</i> , 2020, 99, e20149.	0.4	4
484	Predictive Value of Molecular Subtypes in Premenopausal Women with Hormone Receptor-positive Early Breast Cancer: Results from the ABCSG Trial 5. <i>Clinical Cancer Research</i> , 2020, 26, 5682-5688.	3.2	4
485	Cytotoxic constituents and a new hydroxycinnamic acid derivative from <i>Leontodon saxatilis</i> (Asteraceae, Cichorieae). <i>RSC Advances</i> , 2021, 11, 10489-10496.	1.7	4
486	Spatial Heterogeneity in Large Resected Diffuse Large B-Cell Lymphoma Bulks Analysed by Massively Parallel Sequencing of Multiple Synchronous Biopsies. <i>Cancers</i> , 2021, 13, 650.	1.7	4

#	ARTICLE	IF	CITATIONS
487	Sustained response to brigatinib in a patient with refractory metastatic pheochromocytoma harboring R1192P anaplastic lymphoma kinase mutation: a case report from the Austrian Group Medical Tumor Therapy next-generation sequencing registry and discussion of the literature. <i>ESMO Open</i> , 2021, 6, 100233.	2.0	4
488	Postoperative chemoradiotherapy with cisplatin is superior to radioimmunotherapy with cetuximab and radiotherapy alone. <i>Wiener Klinische Wochenschrift</i> , 2021, 133, 1131-1136.	1.0	4
489	Non-pegylated Liposomal Doxorubicin as Palliative Chemotherapy in pre-Treated Advanced Pancreatic Cancer: A Retrospective Analysis of Twenty-Eight Patients. <i>Technology in Cancer Research and Treatment</i> , 2021, 20, 153303382110421.	0.8	4
490	Myelodysplastic Syndromes (MDS). , 2010, , 153-222.		4
491	AOP2014, a Novel Peg-Proline-Interferon Alpha-2b with Improved Pharmacokinetic Properties, Is Safe and Well Tolerated and Shows Promising Efficacy in Patients with Polycythemia Vera (PV). <i>Blood</i> , 2012, 120, 175-175.	0.6	4
492	Bevacizumab (BEV) continued beyond first progression in patients (pts) with metastatic colorectal cancer (mCRC) previously treated with BEV + chemotherapy (CT): Biomarker findings from ML18147.. <i>Journal of Clinical Oncology</i> , 2013, 31, 452-452.	0.8	4
493	Follicle stimulating hormone (FSH) as a surrogate parameter for the effectiveness of endocrine therapy with or without zoledronic acid in premenopausal patients with breast cancer: An analysis of the prospective ABCSG-12 trial.. <i>Journal of Clinical Oncology</i> , 2014, 32, 577-577.	0.8	4
494	Abstract P2-07-12: Triple negative breast cancer subtypes and early dynamics of the 27-gene IO score predict pCR in the NeoTRIPaPDL1 trial. <i>Cancer Research</i> , 2022, 82, P2-07-12-P2-07-12.	0.4	4
495	Adverse Events in 1406 Patients Receiving 13,780 Cycles of Azacitidine within the Austrian Registry of Hypomethylating Agentsâ€”A Prospective Cohort Study of the AGMT Study-Group. <i>Cancers</i> , 2022, 14, 2459.	1.7	4
496	Topical evening primrose oil for reduction of bortezomib-induced skin reactions. <i>Annals of Hematology</i> , 2013, 92, 995-996.	0.8	3
497	Use of romiplostim allows for hepatitis C therapy in a HIV/HCV coinfecting patient. <i>Annals of Hematology</i> , 2013, 92, 1001-1002.	0.8	3
498	Overcoming Resistance Against HER2-Targeting Agents in Fifth-Line Therapy: Is There Still a Place for Bevacizumab in HER2+ Breast Cancer?. <i>Clinical Breast Cancer</i> , 2014, 14, e17-e20.	1.1	3
499	A patient diagnosed with BRAF-mutated non-small cell lung cancer and hairy cell leukemia: at last, which entity is really carrying the BRAF mutation?. <i>Annals of Hematology</i> , 2015, 94, 345-346.	0.8	3
500	Treatment of aggressive B-cell lymphoma in elderly patients: influence of single nucleotide polymorphisms affecting pharmacodynamics of chemotherapeutics. <i>Leukemia and Lymphoma</i> , 2015, 56, 353-360.	0.6	3
501	Intermittent low-dose bevacizumab in hereditary hemorrhagic telangiectasia. <i>Wiener Klinische Wochenschrift</i> , 2017, 129, 141-144.	1.0	3
502	Hospitalizations and Clinical Outcome in Metastatic Colorectal Cancer During Regorafenib or TAS-102 Therapy. <i>Cancers</i> , 2020, 12, 2812.	1.7	3
503	Reduced alpha diversity of the oral microbiome correlates with short progression-free survival in patients with relapsed/refractory multiple myeloma treated with ixazomib-based therapy (AGMT MM 1). <i>Tj ETQq10140.784314 rgBT</i>		
504	Olaratumab plus anthracycline in advanced/metastatic soft tissue sarcoma. <i>Wiener Klinische Wochenschrift</i> , 2021, 133, 21-25.	1.0	3

#	ARTICLE	IF	CITATIONS
505	Transferring MINDACT to Daily Routine: Implementation of the 70-Gene Signature in Luminal Early Breast Cancer – Results from a Prospective Registry of the Austrian Group Medical Tumor Therapy (AGMT). <i>Breast Care</i> , 2022, 17, 1-9.	0.8	3
506	Conventional versus reverse sequence of neoadjuvant epirubicin/cyclophosphamide and docetaxel: sequencing results from ABCSG-34. <i>British Journal of Cancer</i> , 2021, 124, 1795-1802.	2.9	3
507	Results of a hospitalization policy of asymptomatic and pre-symptomatic COVID-19-positive long-term care facility residents in the province of Salzburg – a report from the AGMT COVID-19 Registry. <i>GeroScience</i> , 2021, 43, 1877-1897.	2.1	3
508	Two Cases of Pancytopenia with Coombs-Negative Hemolytic Anemia after Chimeric Antigen Receptor T-Cell Therapy. <i>International Journal of Molecular Sciences</i> , 2021, 22, 5449.	1.8	3
509	Cytotoxic Compounds of Two Demosponges (<i>Aplysina aerophoba</i> and <i>Spongia</i> sp.) from the Aegean Sea. <i>Biomolecules</i> , 2021, 11, 723.	1.8	3
510	The Role of Neutrophilic Granulocytes in Philadelphia Chromosome Negative Myeloproliferative Neoplasms. <i>International Journal of Molecular Sciences</i> , 2021, 22, 9555.	1.8	3
511	Pharmacodynamic Analysis Of The Inhibitory Potency Of The Tyrosine Kinase Inhibitor Midostaurin In Combination With Intensive Chemotherapy Including Allogeneic Hematopoietic Stem Cell Transplantation Followed By Maintenance Therapy In FLT3-ITD Positive Acute Myeloid Leukemia In The Ongoing AMLSG 16-10 Trial. <i>Blood</i> , 2013, 122, 1283-1283.	0.6	3
512	Anti-CXCL12/SDF-1 Spiegelmer® Nox-A12 Alone and In Combination With Bortezomib and Dexamethasone In Patients With Relapsed Multiple Myeloma: Results From A Phase Ila Study. <i>Blood</i> , 2013, 122, 1951-1951.	0.6	3
513	Azacitidine in Acute Myeloid Leukemia: Comparison of Patients with AML-MRF Vs AML-NOS Enrolled in the Austrian Azacitidine Registry. <i>Blood</i> , 2014, 124, 3681-3681.	0.6	3
514	Is It Time to Redefine Response in Elderly Patients with WHO-Acute Myeloid Leukemia (AML) Unfit for Intensive Chemotherapy?. <i>Blood</i> , 2015, 126, 3742-3742.	0.6	3
515	Lysine Residue at Position 22 of the AID Protein Regulates Its Class Switch Activity. <i>PLoS ONE</i> , 2012, 7, e30667.	1.1	3
516	Leveraging immune memory against measles virus as an antitumor strategy in a preclinical model of aggressive squamous cell carcinoma. , 2021, 9, e002170.		3
517	Differential Sensitivity of CD4+ and CD8+ T Lymphocytes to the Killing Efficacy of Fas (Apo-1/CD95) Ligand+ Tumor Cells in B Chronic Lymphocytic Leukemia. <i>Blood</i> , 1998, 91, 4273-4281.	0.6	3
518	Scalable Enrichment of Immunomodulatory Human Acute Myeloid Leukemia Cell Line-Derived Extracellular Vesicles. <i>Cells</i> , 2021, 10, 3321.	1.8	3
519	Capecitabine in combination with bendamustine in pretreated women with HER2-negative metastatic breast cancer: results of a phase II trial (AGMT MBC-6). <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592110423.	1.4	3
520	Kindlin-3 maintains marginal zone B cells but confines follicular B cell activation and differentiation. <i>Journal of Leukocyte Biology</i> , 2021, , .	1.5	3
521	Detecting Bacterial – Human Lateral Gene Transfer in Chronic Lymphocytic Leukemia. <i>International Journal of Molecular Sciences</i> , 2022, 23, 1094.	1.8	3
522	Checkpoint inhibitors in metastatic gastric and GEJ cancer: a multi-institutional retrospective analysis of real-world data in a Western cohort. <i>BMC Cancer</i> , 2022, 22, 51.	1.1	3

#	ARTICLE	IF	CITATIONS
523	The effect of IgVH mutational status on the induction of apoptosis by rituximab in patients with heavily pretreated B-cell chronic lymphocytic leukemia: evidence from a clinical phase I/II trial. <i>Haematologica</i> , 2006, 91, 1291-3.	1.7	3
524	Abstract PD10-06: Predictive value of RT-qPCR 27-gene IO score and comparison with RNA-Seq IO score in the NeoTRIPaPDL1 trial. <i>Cancer Research</i> , 2022, 82, PD10-06-PD10-06.	0.4	3
525	Phase 1/2a trial of nadunolimab, a first-in-class fully humanized monoclonal antibody against IL1RAP, in combination with gemcitabine and nab-paclitaxel (GN) in patients with pancreatic adenocarcinoma (PDAC).. <i>Journal of Clinical Oncology</i> , 2022, 40, 4141-4141.	0.8	3
526	Einsatz hÄmatopoetischer Wachstumsfaktoren in der Therapie hÄmatologischer und onkologischer Krankheiten. <i>Oncology Research and Treatment</i> , 1998, 21, 527-532.	0.8	2
527	Is Chemoendocrine Treatment without Alternative?. <i>Breast Care</i> , 2008, 3, 231-235.	0.8	2
528	The Dark Side of the Moon – the Side Effects of Therapy in a Dynamic Era of Breast Cancer Management. <i>Breast Care</i> , 2009, 4, 144-147.	0.8	2
529	A new trisaccharide derivative from <i>Prenanthes purpurea</i> . <i>Journal of the Serbian Chemical Society</i> , 2011, 76, 841-845.	0.4	2
530	Human immunodeficiency virus type 2 infections in Austria. <i>Wiener Klinische Wochenschrift</i> , 2014, 126, 212-216.	1.0	2
531	MDM2 promotor polymorphism and disease characteristics in chronic lymphocytic leukemia: results of an individual patient data-based meta-analysis. <i>Haematologica</i> , 2014, 99, 1285-1291.	1.7	2
532	Remission maintenance treatment options in chronic lymphocytic leukemia. <i>Cancer Treatment Reviews</i> , 2018, 70, 56-66.	3.4	2
533	Pixantrone demonstrates significant in vitro activity against multiple myeloma and plasma cell leukemia. <i>Annals of Hematology</i> , 2019, 98, 2569-2578.	0.8	2
534	TCL1 transgenic mice as a model for CD49d-high chronic lymphocytic leukemia. <i>Leukemia</i> , 2020, 34, 2498-2502.	3.3	2
535	Overcoming negative predictions of microRNA expressions to gemcitabine response with FOLFIRINOX in advanced pancreatic cancer patients. <i>Future Science OA</i> , 2021, 7, FSO644.	0.9	2
536	Safety, tolerability and preliminary efficacy of CAN04, a first in class monoclonal antibody against IL1RAP, in combination with nab-paclitaxel and gemcitabine (NG) in subjects with pancreatic cancer.. <i>Journal of Clinical Oncology</i> , 2021, 39, e16228-e16228.	0.8	2
537	A POLE Splice Site Deletion Detected in a Patient with Biclonal CLL and Prostate Cancer: A Case Report. <i>International Journal of Molecular Sciences</i> , 2021, 22, 9410.	1.8	2
538	Activity of Azacitidine in 26 Unselected, Consecutive CMML Patients Included in the Austrian Azacitidine Registry (AAR) of the AGMT-Study Group. <i>Blood</i> , 2011, 118, 1715-1715.	0.6	2
539	Azacitidine in Patients with Treatment-Related Acute Myeloid Leukemia: Retrospective Analysis of the Austrian Azacitidine Registry. <i>Blood</i> , 2014, 124, 2284-2284.	0.6	2
540	Azacitidine in Patients with Relapsed/Refractory Acute Myeloid Leukemia : Retrospective Analysis of the Austrian Azacitidine Registry. <i>Blood</i> , 2014, 124, 943-943.	0.6	2

#	ARTICLE	IF	CITATIONS
541	Azacitidine in Older Patients with Acute Myeloid Leukemia (AML). Results from the Expanded International E-Alma Series (E-ALMA+) According to the MRC Risk Index Score. <i>Blood</i> , 2015, 126, 2554-2554.	0.6	2
542	The effect of exercise training on endothelial function in postmenopausal women with breast cancer under aromatase inhibitor therapy. <i>Cancer Medicine</i> , 2022, 11, 4946-4953.	1.3	2
543	EXTENSIVE MENINGEAL INVOLVEMENT AS THE PRIMARY MANIFESTATION OF A SYSTEMIC SMALL LYMPHOCYTIC LYMPHOMA: FAVOURABLE OUTCOME AFTER NEURAXIAL IRRADIATION WITHOUT CHEMOTHERAPY. <i>British Journal of Haematology</i> , 1993, 83, 674-675.	1.2	1
544	MicroRNAs as biomarkers for the diagnosis and prognosis of human cancer. <i>Journal of Nucleic Acids Investigation</i> , 2010, 1, 14.	0.5	1
545	Complete Remission of Waldenström Macroglobulinemia With Azacitidine and Rituximab. <i>Journal of Clinical Oncology</i> , 2011, 29, e696-e698.	0.8	1
546	ASH 2012 update chronic lymphocytic leukemia—the best is yet to come. <i>Memo - Magazine of European Medical Oncology</i> , 2013, 6, 177-180.	0.3	1
547	What's new in Hodgkin's lymphoma: ASH 2012 and more. <i>Memo - Magazine of European Medical Oncology</i> , 2013, 6, 193-196.	0.3	1
548	Management of immunosuppression in the treatment of chronic lymphocytic leukemia. <i>Memo - Magazine of European Medical Oncology</i> , 2013, 6, 37-40.	0.3	1
549	88. <i>Cytokine</i> , 2013, 63, 264.	1.4	1
550	Complications of 5-azacytidine: Three cases of severe ischemic colitis in elderly patients with myelodysplastic syndrome. <i>Oncology Letters</i> , 2013, 6, 1756-1758.	0.8	1
551	Multi-gene signatures in breast cancer: actual clinical impact. <i>Memo - Magazine of European Medical Oncology</i> , 2014, 7, 16-21.	0.3	1
552	Malignant Lymphoblasts in T Cell Acute Lymphoblastic Leukemia Express High Levels of Kv1.3. <i>Biophysical Journal</i> , 2014, 106, 551a.	0.2	1
553	Response to comment by P. Vassilikopoulos and colleagues. <i>Haematologica</i> , 2015, 100, e482-e482.	1.7	1
554	Treatment of Patients With Myelodysplastic Syndrome With Lenalidomide in Clinical Routine in Austria. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015, 15, e143-e149.	0.2	1
555	Panitumumab-Associated Encephalopathy after Accidental Intra-arterial Application through Dislocated Central Venous Access Device. <i>Frontiers in Neurology</i> , 2016, 7, 196.	1.1	1
556	Systemic treatment of metastatic breast cancer: SABCS 2018. <i>Memo - Magazine of European Medical Oncology</i> , 2019, 12, 253-256.	0.3	1
557	Benefit of second-line therapy for advanced esophageal squamous cell carcinoma: a tri-center propensity score analysis. <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592110399.	1.4	1
558	Ramucirumab plus FOLFIRI or irinotecan as second-line therapy in advanced or metastatic gastric or gastroesophageal junction adenocarcinoma. <i>Journal of Gastrointestinal Oncology</i> , 2021, 12, 906-909.	0.6	1

#	ARTICLE	IF	CITATIONS
559	Evidence for Non-Cancer-Specific T Cell Exhaustion in the Tc1 Mouse Model for Chronic Lymphocytic Leukemia. <i>International Journal of Molecular Sciences</i> , 2021, 22, 6648.	1.8	1
560	The OncoMasTR Test Predicts Distant Recurrence in Estrogen Receptor-Positive, HER2-Negative Early-Stage Breast Cancer: A Validation Study in ABCSC Trial 8. <i>Clinical Cancer Research</i> , 2021, 27, 5931-5938.	3.2	1
561	Top 3 Abstracts concerning hormone-receptor-positive early breast cancer. <i>Memo - Magazine of European Medical Oncology</i> , 2021, 14, 252-256.	0.3	1
562	Abstract P4-07-03: MicroRNAs correlating with outcome in patients treated with first-line bevacizumab for metastatic breast cancer. , 2015, , .		1
563	Final Analysis of Induction Treatment with Fludarabine, Cyclophosphamide Plus Rituximab (FCR) Followed by Fludarabine Plus Rituximab (FR) and Remission Maintenance Therapy with Rituximab in Previously Untreated B-Chronic Lymphocytic Leukemia (B-CLL): The Chairou AGMT CLL4/Roche ML18434 Study. <i>Blood</i> . 2010. 116. 1380-1380.	0.6	1
564	Analysis Of Molecular Responses and Chromosomal Aberrations In Patients With Polycythemia Vera Treated With Peg-Proline-Interferon Alpha-2b (AOP2014/P1101) In The Peginvera Study. <i>Blood</i> , 2013, 122, 1589-1589.	0.6	1
565	Azacitidine in Patients with Acute Myeloid Leukemia: Assessing the Potential Negative Impact of Elevated Baseline White Blood Cell Count on Outcome. <i>Blood</i> , 2014, 124, 3683-3683.	0.6	1
566	Molecular Characterization of Relapsed Core-Binding Factor (CBF) Acute Myeloid Leukemia (AML). <i>Blood</i> , 2015, 126, 2586-2586.	0.6	1
567	Bevacizumab (BEV) plus chemotherapy (CT) continued beyond first disease progression (PD) in patients with metastatic colorectal cancer (mCRC) previously treated with BEV-based therapy: Outcomes according to KRAS status and first-line CT backbone in the ML18147 study.. <i>Journal of Clinical Oncology</i> . 2014. 32. 520-520.	0.8	1
568	Influence of immunohistological detection of intratumoral urokinase-type plasminogen activator (uPA) on disease outcome in endocrine-treated postmenopausal patients with hormone receptor-positive early breast cancer.. <i>Journal of Clinical Oncology</i> , 2015, 33, 551-551.	0.8	1
569	Soluble CD87 (s-uPAR) predicts bevacizumab-based first line treatment of metastatic colorectal cancer (mCRC): Results from a prospective multi-center study.. <i>Journal of Clinical Oncology</i> , 2017, 35, 604-604.	0.8	1
570	Dose tailoring of breast cancer adjuvant chemotherapy aiming at avoiding both over and undertreatment: Results from the prospective PANTHER study.. <i>Journal of Clinical Oncology</i> , 2018, 36, 538-538.	0.8	1
571	Abstract 603: CAL-101 acts synergistic with arsenic trioxide in chronic lymphocytic leukemia by preventing p21 phosphorylation through AKT1.. , 2013, , .		1
572	Capecitabine in combination with bendamustine in pretreated women with HER2-negative metastatic breast cancer: results of a phase II trial (AGMT MBC-6). <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 17588359211042301.	1.4	1
573	Abstract P1-21-08: Brain metastases (BM) from breast cancer: Real-word data from the Austrian AGMT_MBC-registry. <i>Cancer Research</i> , 2022, 82, P1-21-08-P1-21-08.	0.4	1
574	Klinische Praxis Aromataseinhibitoren: Upfront, Switch oder Extended?. <i>Breast Care</i> , 2006, 1, 37-43.	0.8	0
575	Adjuvanter Einsatz von Trastuzumab (Herceptin®) in der klinischen Praxis außerhalb von klinischen Studien. <i>Breast Care</i> , 2006, 1, 96-101.	0.8	0
576	What paths are open for tackling increasing azole resistance in <i>Aspergillus</i> in the clinic?. <i>Expert Review of Anti-Infective Therapy</i> , 2012, 10, 1229-1231.	2.0	0

#	ARTICLE	IF	CITATIONS
577	Treating T-cell lymphoma: is there a light at the end of the tunnel?. Memo - Magazine of European Medical Oncology, 2012, 5, 174-177.	0.3	0
578	A 55-year-old woman with locally advanced rectal cancer and a resectable synchronous hepatic metastasis: a case report. Memo - Magazine of European Medical Oncology, 2012, 5, 273-276.	0.3	0
579	Therapy with JAK 1/2 inhibitors for myelofibrosis. Memo - Magazine of European Medical Oncology, 2013, 6, 109-113.	0.3	0
580	Pleural decortication of a marginal zone lymphoma. Annals of Hematology, 2014, 93, 1253-1254.	0.8	0
581	ASCO-update: gastrointestinal tumors. Memo - Magazine of European Medical Oncology, 2017, 10, 240-243.	0.3	0
582	The first meeting of the Austrian Expert Panel for Molecular Cancer Profiling. Memo - Magazine of European Medical Oncology, 2017, 10, 255-258.	0.3	0
583	Establishment and validation of a novel risk model for estimating time to first treatment in 120 patients with chronic myelomonocytic leukaemia. Wiener Klinische Wochenschrift, 2018, 130, 115-125.	1.0	0
584	A multicenter retrospective evaluation of Chronic Myeloid Leukemia (CML) therapy in Austria assessing the impact of early treatment response on patient outcomes in a real-life setting. Wiener Klinische Wochenschrift, 2020, 132, 415-422.	1.0	0
585	Complete remission of disseminated Langerhans cell sarcoma after stem cell transplantation. Memo - Magazine of European Medical Oncology, 2020, 13, 102-105.	0.3	0
586	Influence of Height on Risk and Outcome of Patients with Early Breast Cancer: A Pooled Analysis of 4,925 Patients from 5 Randomized Trials of the Austrian Breast and Colorectal Cancer Study Group (ABCSCG). Breast Care, 0, , 1-9.	0.8	0
587	Antiproliferative and Proapoptotic Effects of Akacid-Medical-Formulation on Hematologic Cell Lines.. Blood, 2006, 108, 4380-4380.	0.6	0
588	Essential Thrombocythemia (ET). , 2010, , 15-50.		0
589	Primary Myelofibrosis (PMF) [Previously Chronic Idiopathic Myelofibrosid (CIMF), Myelofibrosis with Myeloid Metaplasia (MMM), Agnogenic Myeloid Metaplasia (AMM)]. , 2010, , 81-116.		0
590	Clonal Bone Marrow Failure Overlap Syndromes. , 2010, , 281-288.		0
591	Introduction to "Classic" Chronic Myeloproliferative Disorders (CMPDs) Molecular and Cellular Biology. , 2010, , 1-13.		0
592	Isocitrate Dehydrogenase Gene Mutations In Elderly Patients with Acute Myeloid Leukemia (AML) and Outcome After Treatment with All-Trans Retinoic Acid: A Study of the German-Austrian AML Study Group (AMSLG). Blood, 2010, 116, 101-101.	0.6	0
593	Abstract 2273: Validation of putative stem cell factor SOX2 as predictive marker in breast cancer with overall poor prognosis. , 2011, , .		0
594	Abstract 1108: Subtype specific expression of immune-modulating miR-155 and miR-146a in anaplastic large cell lymphoma. , 2012, , .		0

#	ARTICLE	IF	CITATIONS
595	T Cell Exhaustion Contributes to Immune Evasion in Chronic Lymphocytic Leukaemia. <i>Blood</i> , 2012, 120, 1773-1773.	0.6	0
596	Chronic Lymphocytic Leukemia Cells With Trisomy 12 Home To The Bone Marrow In a CXCR4-Independent Manner and Are Prone To Proliferate In Vitro. <i>Blood</i> , 2013, 122, 870-870.	0.6	0
597	Early PK-Analysis Predicts Molecular Response In Patients With Early Chronic Phase Chronic Myelogenous Leukemia (CML-CP) Treated With Frontline Nilotinib. <i>Blood</i> , 2013, 122, 1485-1485.	0.6	0
598	Immune Monitoring In Patients With Early Chronic Phase Chronic Myelogenous Leukemia (CML-CP) Treated With Frontline Nilotinib. <i>Blood</i> , 2013, 122, 2731-2731.	0.6	0
599	A randomized, double-blind, placebo-controlled, multicenter, binational, phase II trial of immunotherapy with L-BLP25 (tecemotide) in patients with colorectal carcinoma following R0/R1 hepatic metastasectomy.. <i>Journal of Clinical Oncology</i> , 2014, 32, TPS3658-TPS3658.	0.8	0
600	Impact of Donor Type on Outcome after Allogeneic Stem Cell Transplantation in Acute Myeloid Leukemia Patients: Analysis of the German-Austrian Acute Myeloid Leukemia Study Group (AMLSG). <i>Blood</i> , 2014, 124, 1254-1254.	0.6	0
601	The Transcription Factor IRF4 Is Crucial for CLL Progression and Regulates Survival and Proliferation in a Microenvironment Related Manner. <i>Blood</i> , 2014, 124, 1973-1973.	0.6	0
602	Switch from Every Two Weeks to Every Four Weeks Administration Schedule of AOP2014, an Innovative Pegylated Interferon Alpha, in Polycythemia Very Patients Allows Maintaining of Efficacy with Improved Toxicity Profile in Phase I/II Study. <i>Blood</i> , 2014, 124, 3177-3177.	0.6	0
603	Spliceosome Mediated RNA Trans-Splicing for Targeting Kappa+ B-Cell Neoplasms. <i>Blood</i> , 2014, 124, 3633-3633.	0.6	0
604	Clonal Evolution in Relapsed or Refractory Diffuse Large B Cell Lymphoma. <i>Blood</i> , 2014, 124, 77-77.	0.6	0
605	Amphiregulin (AREG) expression and response to first-line panitumumab (pmab) plus FOLFIRI in metastatic colorectal cancer (mCRC).. <i>Journal of Clinical Oncology</i> , 2015, 33, 731-731.	0.8	0
606	Abstract P6-08-47: Androgen receptor expression in pre-menopausal early breast cancer patients treated with endocrine therapy within the ABCSG-12 trial - a single center pilot analysis. , 2015, , .		0
607	Expression of amphiregulin (AREG) and response to first-line panitumumab (pmab) + FOLFIRI in metastatic colorectal cancer (mCRC).. <i>Journal of Clinical Oncology</i> , 2015, 33, 3536-3536.	0.8	0
608	DYPD genotyping to predict toxicity in patients with stage III colon cancer treated with 5-fluorouracil-based adjuvant chemotherapy in the PETACC-8 phase III trial.. <i>Journal of Clinical Oncology</i> , 2015, 33, 3584-3584.	0.8	0
609	Primary Progressive Disease in Hodgkin Lymphoma Patients: A Retrospective Analysis from the German Hodgkin Study Group. <i>Blood</i> , 2015, 126, 3941-3941.	0.6	0
610	Capecitabine in combination with bendamustine in pretreated women with HER2-negative metastatic breast cancer: Efficacy results of a phase II trial (AGMT MBC-6).. <i>Journal of Clinical Oncology</i> , 2016, 34, 1032-1032.	0.8	0
611	The fibrinogen/CRP ratio as a novel prognostic parameter for pancreatic cancer patients.. <i>Journal of Clinical Oncology</i> , 2016, 34, e15701-e15701.	0.8	0
612	COSMOS: MOR208 plus idelalisib or venetoclax in patients with relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) previously treated with a Bruton's tyrosine kinase inhibitor (BTKi)â€™A two-cohort phase II study.. <i>Journal of Clinical Oncology</i> , 2017, 35, TPS7567-TPS7567.	0.8	0

#	ARTICLE	IF	CITATIONS
613	Risks and chances of aberrant DNA repair in cancer. <i>Oncoscience</i> , 2018, 5, 256-257.	0.9	0
614	A randomized, double-blinded, placebo-controlled multicenter phase II trial of adjuvant immunotherapy with tecemotide (L-BLP25) after R0/R1 hepatic colorectal cancer metastasectomy (LICC): Final results.. <i>Journal of Clinical Oncology</i> , 2019, 37, 3537-3537.	0.8	0
615	Mouse models to decipher anti-tumor immunity. <i>Oncotarget</i> , 2019, 10, 5005-5006.	0.8	0
616	Measurable Residual Disease (MRD) Monitoring in Acute Myeloid Leukemia (AML) with t(8;21)(q22;q22.1) RUNX1-RUNX1T1 Identifies Patients at High Risk of Relapse: Results of the AML Study Group (AMLSG). <i>Blood</i> , 2019, 134, 2740-2740.	0.6	0
617	Brentuximab Vedotin Plus ESHAP (BRESHAP) Versus ESHAP As Salvage Strategy for Patients with Primary Refractory or Relapsed Classical Hodgkin's Lymphoma. Preliminary Results from the Breselibet Prospective Clinical Trial. <i>Blood</i> , 2021, 138, 2459-2459.	0.6	0
618	Composition of the Immune Environment at Baseline Correlates with Time to Response and Treatment Outcome in Newly Diagnosed Transplant-Ineligible Multiple Myeloma (MM) Patients Randomized to Krd or Ktd Followed By Carfilzomib Maintenance or Observation (AGMT_MM 02 Study). <i>Blood</i> , 2021, 138, 1669-1669.	0.6	0
619	Immunophenotyping of Baseline Bone Marrow Reveals a Specific Pattern of Immune Cells Associated with Greater Depth and Sustained Response in Newly Diagnosed Patients Randomized to Krd or Ktd Followed By Carfilzomib Maintenance or Control (AGMT MM 02 Study). <i>Blood</i> , 2020, 136, 29-30.	0.6	0
620	Quality of Life in Newly Diagnosed Patients with Multiple Myeloma Randomized to Either Krd or Ktd Induction Therapy Followed By Carfilzomib Maintenance or Control (AGMT MM 02 trial). <i>Blood</i> , 2020, 136, 27-29.	0.6	0
621	The Integrin Adaptor Kindlin-3 Is Important for Development and Retention of Marginal Zone B Cells. <i>Blood</i> , 2020, 136, 46-47.	0.6	0
622	Phase II Single-Arm "Window-of-Opportunity" Study of a Combination of Obinutuzumab and Venetoclax in Early Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) - First Results of the AGMT NHL15B Study. <i>Blood</i> , 2020, 136, 26-26.	0.6	0
623	Abstract P1-16-03: Response pattern to chemotherapy in metastatic breast cancer (MBC): Real-word data from the Austrian AGMT_MBC-Registry. <i>Cancer Research</i> , 2022, 82, P1-16-03-P1-16-03.	0.4	0
624	Abstract P1-04-02: Immune milieu associated with PD-L1 status in TNBC is dependent on time of biomarker assessment and treatment received: A secondary analysis of the NeoTRIPaPDL1 trial. <i>Cancer Research</i> , 2022, 82, P1-04-02-P1-04-02.	0.4	0